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Abstract 
Nanoparticle Protein Delivery Systems for Nervous Tissue Repair 
Jason J. Coleman 
Advisor:  Anthony M. Lowman, Ph.D. 
 
Nerve regeneration following spinal injury remains one of the most difficult to 
solve medical problems mainly because the spinal tissue environment is not conducive to 
nerve growth.  PLGA nanoparticles offer great potential as a sustained delivery system 
for proteins that promote nerve regeneration.  However, in order for PLGA-particle 
protein delivery in injured spinal tissue to be clinically relevant, various drawbacks 
including: low encapsulation efficiency, protein instability, incomplete protein release 
and particle biocompatibility have to be addressed and overcome. 
This research focuses on developing the water/oil/water (W/O/W) double 
emulsion procedure to physically entrap protein within PLGA particles and 
systematically analyzing the effects on particle morphology, protein loading, protein 
activity and sustained active protein release.  Variables evaluated include solvent 
miscibility, energy input, PLGA concentration, and various additives.  Adjustments to 
formulation parameters had significant advantages on size distribution, loading 
efficiency, protein stability, and increased active protein released.  Most particles 
demonstrated sustained release of active protein over 60 days and a mathematical model 
was developed to illustrate a tri-phasic release profile.   
Because of direct injection into spinal tissue, biocompatibility concerns are 
directly related to particle sterility, surface characteristics and cytotoxicity.  A plasma 
sterilization method was developed that can completely inactivate an E. coli bacteria load 
of 10
3
 CFU/ml while maintaining particle integrity and protein stability.  Surface 
xiv 
 
characteristics were modified by altering the preparation conditions to eliminate residual 
surfactant.  Other surface modification methods included ways to increase surface 
hydrophilicity and these methods involved both PEGylation and plasma treatment.  All 
modification methods resulted in no measurable amount of protein (IgG) adsorbed to the 
particle surface.  Fabrication methods were modified to eliminate particle cytotoxicity.  
Plasma treatment showed no cytotoxic effects, while mPEG-PLGA showed minimum 
cytotoxicity.  PLGA particle degradation showed no impact on cytotoxicity.   
Overall, this research advanced the clinical relevance of a PLGA protein delivery 
system for a multitude of applications.  The drawbacks preventing such a delivery system 
from in vivo use were addressed. 
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1. Chapter 1:  Introduction and Specific Aims 
Nerve regeneration in spinal cord tissue after spinal cord injury is extremely 
difficult for multiple reasons, but mainly because the spinal tissue environment post-
injury is not conducive for axon growth.  The main purpose of this work is to develop an 
injectable and biocompatible nanoparticle protein delivery system that can provide 
sustained release of active protein.  Examples of proteins or protein antibodies used to 
condition the spinal tissue environment for axon growth include neurotrophic factors (i.e. 
BDNF, GDNF, NT-3, etc.), chondroitinase ABC or IN-1 antibodies.  Due to rapid 
enzymatic degradation or activity loss of exogenous delivered proteins in the spinal tissue 
repeated injections or local infusions are necessary over a period of days to weeks [1-3].  
These delivery methods are invasive, aggravating, infection-prone and problematic [1-3].  
Therefore, an injectable submicron particle delivery system that can provide localized 
delivery of various active proteins over the desired time intervals is beneficial.  However, 
in order for an injectable particle protein delivery system to be clinically relevant, several 
drawbacks need to be addressed.  These drawbacks include incomplete protein release, 
protein instability and particle biocompatibility. 
One of the goals of this work is to systematically evaluate numerous factors that 
could impact the effectiveness of protein loaded poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles as an injectable delivery system for proteins into spinal tissue.  The effects 
of solvent miscibility (dichloromethane (DCM), ethyl acetate, acetone), PLGA 
concentration (10–30 mg/ml), energy input (10-25 krpm) and additives in the aqueous 
phase (Bovine Serum Albumin (BSA)) and the organic phase (Sucrose Acetate 
Isobutyrate (SAIB)) on particle size, protein loading, protein delivery and protein activity 
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are assessed.  Since interfacial tension between the aqueous-organic interface is a key 
variable, part of this work is the development of relationships that correlate interfacial 
tension and energy input to particle size, particle dispersity and protein denaturation.   
Work also involves the development of a simplified mathematical model to explain the 
multiphases of protein release from particles.  Previous work involving direct injection of 
PLGA particles into spinal tissue did not address the potential macrophage response [2] 
that was seen in preliminary tissue injection studies.  An additional goal is to address 
various factors, such as sterility, surface characteristics and cytotoxicity that could impact 
particle biocompatibility and the heightened immune response.  All particle sterilization 
techniques available are either damaging or extremely expensive; therefore, it is 
necessary to develop a novel sterilization method that is conducive to submicron protein 
loaded particles.  The novel sterilization method explored utilizes the resuspension of 
particles in water or PBS that has been subjected to a plasma discharge.  The 
effectiveness of this treatment as a sterilizing agent and the impact on particle 
morphology, surface characteristics, protein and protein loaded particles is evaluated.  
Other potential reasons for a heightened immune response to injected particles include 
residual surfactant, opsonin adsorption or cytotoxicty.  Formulation parameters were 
developed to minimize the need for surfactants.  The ability to alter the particle surface 
characteristics through PEGylation or plasma treatment is analyzed and the ability to 
lower opsonin adsorption is determined.  Cytotoxicity studies were performed to evaluate 
any negative impact of PLGA particles, degraded particles, plasma treated particles and 
PEGylated particles on cell survival. 
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Specific aim 1 (Chapter 3):  Analyze the effects of the Water/Oil/Water double 
emulsion procedure process variables on particle size, size distribution and protein 
loading. 
Specific aim 2 (Chapter 4):  Evaluate the effectiveness of PLGA particles as a protein 
delivery system and the ability to deliver active protein.  Develop a protein release model 
to represent a tri-phasic release profile. 
Specific aim 3 (Chapter 5):  Determine effectiveness and viability of indirect plasma 
treatment as a sterilization method for protein loaded PLGA particles.  
Specific aim 4 (Chapter 6):  Modify and characterize particle surface changes through 
minimal surfactant usage, plasma treatment and PEGylation and quantify the ability to 
lower protein (opsonin) adsorption.  Analyze particle cytotoxicity and cytotoxicity after 
surface modification 
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2. Chapter 2:  Background 
2.1 Spinal Cord Anatomy 
  The spinal cord consists of millions of nerve fibers that transmit electrical 
information between the periphery and the brain.  A transverse section of the spinal cord 
shows white matter on the outside, gray matter on the inside and a central canal filled 
with cerebrospinal fluid (CSF) in the center (Fig. 2.1).  The gray matter contains the cell 
bodies of neurons and glia and is the area where the integration and processing of 
information between the peripheral and central nervous systems takes place.  The white 
matter contains ascending and descending tracts of myelinated and unmyelinated nerve 
fibers.  The ascending tracts are bundles of nerve fibers that carry information up the cord 
and the descending tracts are bundles of nerve fibers that carry information down the 
cord.  Neurons are specialized cells that consist of a cell body and axons.  The axons 
extend from the neurons and are grouped together to make up the nerve fibers that carry 
signals up and down the spinal cord.  The spinal cord is protected within the vertebral 
column and has an entire length of approximately 18 inches and a width ranging from ½ 
inch to ¼ inch.  The spinal cord is sheathed in three protective layers known as the pia 
mater (the innermost layer), the arachnoid mater (the middle layer) and the dura mater 
(the outermost layer).  Between the dura mater and the vertebrae is the epidural space 
which consists of adipose tissue and blood vessels [4].  Ultimately, the protective layers 
surrounding the spinal cord are extensive to protect the spinal cord from damage caused 
by physical trauma.  This is necessary because of the disruption caused to normal body 
function if indeed, the spinal cord is damaged. 
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2.2 Spinal Cord Injury 
Spinal cord injury (SCI) is the result of a compression or physical tear to the 
spinal cord resulting in damage to axons and various forms of paralysis.  More than 
200,000 Americans are living with some form of paralysis as the result of SCI with 
approximately 12,000 new cases each year [5].  Common causes of spinal cord injury are 
vehicular accidents (41.3%), accidental falls (27.3%), violence (15.0%), sports (7.9%), 
and other (8.5%) [5]. Less than 1% of patients with varying levels of tetraplegia or 
paraplegia experience complete neurological recovery upon hospital discharge [5].  
Spinal cord injury is so damaging, both because of the damage cause by the injury itself, 
but also because of the body’s response to the injury.  A cross-section representing the 
damage caused by the primary and secondary damage is shown in Figure 2.2.  Following 
the injury, primary damage results in the patient entering spinal shock and the spinal cord 
beginning to swell.  During this primary phase, the swelling of the spinal cord results in 
the restriction of blood flow and oxygen transport to the injury sight [6, 7].  Secondary 
damage results in continuous harm to surrounding axons.  Some destructive results of 
secondary damage are: excessive release of neurotransmitters that kill nerve cells; 
invasion of immune cells from the broken blood vessels causing an inflammatory 
response; free radicals formed as a result of the heightened inflammatory response attack 
and disable molecules that are crucial for cell function; and injured nerve cells undergo 
apoptosis [8]. 
The regeneration and reconnection of nerves following spinal cord injury remains 
one of the most difficult to solve medical problems.  Regeneration and reconnection of 
damaged nerves is a difficult task because of both environmental (extrinsic) factors and 
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intrinsic factors to the neuron [9]. The environment within spinal cord tissue is not 
conducive to nerve growth because of physical and molecular barriers.  Various work has 
been done to identify the types proteins (both promotional and inhibitory) responsible for 
this inadequate environment [10-14].   
2.3 Spinal Cord Environment (Barriers to Nerve Repair) 
2.3.1 Physical Barrier 
Following spinal cord injury, the formation of a dense glial scar has been found to 
cause a major physical barrier towards nerve regeneration [9, 15-22].  Figure 2.2 
illustrates the glial scar surrounding the fluid-filled cyst created by the injury.  The role of 
the glial scar is to isolate the injured area from the healthy nervous tissue and forms an 
astrocytic boundary, consisting of type IV collagen and various membrane proteins [9, 
23].  The glial scar typically forms parallel to the border of the wound within 2 - 3 weeks 
[9, 24, 25] so efforts are necessary to either limit the scar formation, or if already 
developed, to either bypass or breakdown the scar tissue in order to allow for axon 
growth.  While studies have demonstrated that the glial scar creates a physical barrier, 
studies have also shown that axons can grow over astrocytes and astrocytic scar tissue 
[26-29], indicating that the physical barrier imposed by the glial scar is not the only 
impedance to axonal growth. 
2.3.2 Molecular Barriers (Extrinsic Factors) 
The environmental factors include both physical and molecular barriers.  The 
formation of a dense glial scar at the injury site provides both a physical and molecular 
impediment to axonal regeneration[9, 15, 16, 18-22, 30, 31].  Following injury, there is 
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an upregulation of various axonal growth inhibitors within the glial scar [32, 33].  Most 
interest has focused on astrocyte produced glycoproteins, chondroitin sulphate 
proteoglycans (CSPGs), capable of inhibiting neurite outgrowth [13, 31, 34].  Recent 
studies have focused on the enzymatic removal of CSPGs through repeated 
administration of the protein chondroitinase ABC to stimulate axonal regeneration into 
the glial scar [30, 35-37].  Other molecular barriers can either inhibit growth directly or 
inhibit growth by the lack of their presence in spinal tissue.  One such inhibitory 
molecule is a myelin inhibitor protein called Nogo-A and the administration of 
antibodies, specifically IN-1 antibodies, resulted in improved nerve regeneration and 
sprouting [12, 38].  Improving the environmental cues to initiate and propagate axonal 
regeneration has been accomplished by the exogenous administration of neurotrophic 
factors (NTFs) [11, 39-43].  Endogenous neurotrophic factor production is increased in 
the peri-wound area weeks after the CNS injury [9]. Production is primarily from 
activated macrophages and microglia [9].  The macrophages and microglia have been 
shown to stimulate outgrowth of axons from the wound core to the wound edge by 
creating a gradient of NTFs, most notably, BDNF and GDNF [9, 44].  The highest 
concentrations of NTFs are produced at the wound margin, where the sprouting axons 
grow towards, but the absence of NTFs outside of the wound perimeter does not allow 
the growing axons to extend further [45].   
2.4 Treatment Options 
Due to the difficulty in promoting nerve regeneration across the injury sight, 
surgical grafts have been employed to bypass the injury sight and provide a more suitable 
environment for nerve growth [9, 16, 46-49].  Polymer scaffolds have also been created 
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that can be tailored to provide a suitable environment for nerve growth [6, 50].  However, 
for nerve regeneration and reconnection to be successful, nerve outgrowth into spinal 
tissue is required.  
Perhaps the most popular treatment option involves the injection of stem cells in 
hopes that the stem cells differentiate into both neurons and glia [9].  Unfortunately, for 
the right differentiation to occur, the environment must be properly conditioned. 
Efforts have been made to alter the characteristic of the spinal cord environment 
to make it more conducive for nerve growth.  Because peripheral nerves are conducive 
for nerve growth, components of peripheral nerves, mainly Schwann cells, have been 
implanted into spinal tissue to generate nerve growth [51, 52].  Schwann cells are 
potentially effective at promoting nerve regeneration because of their ability to secrete 
NTFs [51, 52].  Unfortunately, the delivery of NTFs through the implantation of 
Schwann cells is difficult to control.   
Because of various drawbacks of the treatment options mentioned above, the 
focus of this work is the development of an injectable delivery system that can provide 
the necessary extrinsic factors to improve the spinal cord tissue environment and promote 
nerve regeneration and outgrowth. 
2.5 Nanoparticle Protein Delivery System for Spinal Cord Repair 
Due to the benefits of NTF concentration gradients for promoting axon growth, 
the indication is that continuous delivery and the establishment of NTF concentration 
gradients within spinal tissue can result in directional growth of axons.  Because of the 
potential enzymatic degradation of chondroitinase ABC, IN-1 antibodies and growth 
factors in vivo long term delivery requires either repeated injections or an osmotic 
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minipump, both of which have undesirable side effects such as tissue damage and 
aggravation [2] or complete system failure [30].  The proposed delivery system will 
consist of poly(lactide-co-glycolide) (PLGA) nano- sized particles that can be loaded 
with the desired protein and micro-injected directly into the CNS tissue.  This would be a 
one-time injection that could overcome the undesirable side effects of other delivery 
methods.   
Because injection of particles directly into spinal tissue is a fairly novel concept, 
there is not a specific particle size that is desired.  Some work has been done to 
investigate the biodistribution of particles (20 nm and 100 nm) injected into spinal tissue 
[2].  Results indicated nanoparticles with a size of 20 nm could be easily taken up by 
neurons, while the 100 nm nanoparticles were mainly restricted to the injection site or 
possibly transported in the central canal [2].  Because the desire is for the particles to stay 
localized to the injection site, a particle minimum diameter of 100 nm was chosen.  While 
there has been no work performed to establish a maximum particle diameter, a maximum 
particle diameter of 1 micron was chosen for the following reasons:  ease of injection, to 
minimize damage upon injection and to minimize interference with growing axons.  For 
the utilization of nanoparticles as an intraspinal protein delivery system, it is important to 
develop particles within the desired size range that can deliver active protein over time 
intervals ranging from days to weeks 
2.6 Biodegradable Micro/Nanoparticles for Protein Delivery 
2.6.1 Poly (lactic-co-glycolic acid) (PLGA) 
Poly (lactic-co-glycolic acid) (PLGA) is a biodegradable polymer because it can 
degrade into lactic and glycolic acids which are metabolized within the body.  Because 
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PLGA degrades through hydrolysis the dissolution of water into the polymer matrix 
greatly affects the degradation rate (Fig. 2.3a).  Therefore, the most common way to 
control the dissolution of water within a PLGA matrix is to control the lactide to 
glycolide ratio.  The lactide and glycolide monometers are illustrated in Figure 2.3b.  
Because glycolide lacks the –CH3 group it is a more hydrophilic monomer.  Thus, 
increasing the ratio of glycolide to lactide increases the hydrophilicity of the copolymer, 
increases the water uptake within the copolymer matrix, and as a result, increases the 
degradation rate.  A higher glycolide ratio of PLGA also promotes bulk erosion when the 
copolymer is fabricated in particle form [53].  Molecular weight also has an impact on the 
total degradation of the copolymer and copolymers with higher molecular weights have 
increased degradation times.  For purposes of this work and based on manufacturer 
recommendations, a lactide to glycolide ratio of 50:50 and PLGA molecular weight of 
approximately 18 kDa was used in order to promote polymer degradation and complete 
protein release within one to two months. 
2.6.2 Particles as a Therapeutic Protein Delivery System 
The proposed delivery system will consist of PLGA particles that can be 
physically loaded with the desired protein and micro-injected directly into the CNS 
tissue.  Because little work has been done to investigate the biodistribution of particles 
injected into spinal tissue it is important to develop particles of varying size that can 
deliver active protein over time intervals ranging from days to weeks [2].  It is necessary 
to analyze loading efficiencies of protein into particles because of the high cost of the 
proteins mentioned earlier.  It is also necessary to assess protein damage caused by 
preparation conditions and make the necessary changes to limit protein denaturation.  
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Particle preparation utilizes a physical entrapment method that can be applied to various 
proteins and allows for the use of a model protein, lysozyme, to assess protein loading, 
activity and release.  For ease of injection, to minimize damage upon injection and to 
minimize interference with growing axons, the target particle size is less than 1 micron.  
To reduce uptake by neurons a minimal particle diameter of approximately 100 nm was 
chosen.  Although protein loaded PLGA nanoparticles have been studied as a delivery 
device, only recently have they been considered for direct injection into spinal tissue [2].  
The results were promising but additional work needs to be done that relates particle size 
and formulation parameters to protein loading and active protein released.  Additional 
work also has to be done to minimize the immune response to the injected particles.   
2.6.3 Model Protein 
The model protein lysozyme was used throughout this work because of the ability 
to quantify both the protein amount and activity.  Lysozyme is also similar in both 
molecular weight and isoelectric point to the clinically relevant neurotrophic factors (i.e. 
BDNF, GDNF, NT-3).  Lysozyme has a molecular weight of 14.3 kDa and isoelectric 
point of 11.35.  As an example, BDNF in its dimeric form has a molecular weight of 27.2 
kDa and an isoelectric point of 9.01.  Molecular weight and isoelectric point are 
important parameters when evaluating protein release.  Models of lysozyme and BDNF 
are shown in Figure 2.4. 
2.6.4 Water/Oil/Water Double Emulsion Solvent Evaporation 
The method of particle synthesis is water/oil/water (W/O/W) double emulsion 
solvent evaporation.  This method has been used for the preparation of nano- and micro- 
sized particles [54-62].  This method is necessary when trying to overcome the 
12 
 
thermodynamic barriers associated with entrapping a hydrophilic drug or protein inside 
of a hydrophobic based polymer particle.  It is also the immiscibility between the organic 
or oil phase and the outer aqueous phase that leads to particle formation.  A schematic of 
protein entrapment and particle formation utilizing this procedure is illustrated in Figure 
2.5.  This procedure can best be described in four main steps.  The first step is referred to 
as the primary emulsion phase and it consists of the primary aqueous phase (i.e. dispersed 
phase) that contains the drug or protein of interest and the organic phase (i.e. solvent 
phase) that contains the polymer that will make up the particles.  This primary phase 
requires energy in the form of mixing (stirring, homogenization, or sonication) in order to 
force the interaction between the primary aqueous phase and the organic phase.  The 
second step involves the addition of the primary emulsion to the secondary or outer 
aqueous phase (i.e. continuous phase).  This step requires external energy in the form of 
stirring, homogenizing or sonicating and is the step where the actual particles first begin 
to form.  At this point the particles consist of the primary emulsion which is a 
combination of the drug dissolved in the primary aqueous phase and the polymer 
dissolved in the organic phase.  This secondary aqueous phase typically contains a 
surfactant in order to lower the interfacial tension between the organic phase and the 
external aqueous phase and prevent the organic phase from agglomerating.  The third step 
is referred to as the evaporation or drying step.  During this step the organic solvent is 
allowed to evaporate and leaves the ‘solid’ particles (polymer no longer dissolved in 
solvent) behind.  The final step involves several centrifugation steps in order to collect 
and wash the particles.  After centrifugation, particles can be used right away or stored as 
either a suspended, frozen, or freeze-dried sample. 
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While the method described above represents immiscible or partially miscible 
solvents, the method can also be used with a miscible solvent.  The procedure is similar, 
with only a few differences in how the particles are formed and how the protein is 
entrapped in the particle (Fig. 2.6).  The first step or primary emulsion still involves the 
blending of the primary aqueous phase and the organic phase to force the interaction 
between drug or protein and polymer.  The second step is the addition of the primary 
emulsion to the secondary/outer aqueous phase, but the main difference involves how the 
particles are formed.  At this step, once the primary emulsion is added to the secondary 
aqueous phase, the polymer precipitates out of solution and forms ‘solid’ particles.  Also, 
because the primary emulsion blended the polymer and the drug, then as the polymer 
precipitates out of solution, it can potentially entrap the protein or drug.  The final 
evaporation step is not required to form ‘solid’ particles, but is required for solvent 
removal.   
2.6.5 Particle Size 
 Varying the solvent and homogenization speed are the two variables controlled 
that have the greatest impact on particle size.  For particles formed by an emulsion 
process involving an aqueous-organic interface the particle size can be related to the 
interfacial tension and shear forces generated by homogenization [63].  In general, an 
increase in solvent miscibility results in a decrease in interfacial tension at the aqueous-
organic interface and thus a decrease in particle size [63].  A list of solubility and 
interfacial tension values for the solvents used with respect to water is given in Table 2.1 
[64].  When immiscible and partially miscible solvents are used, increasing 
homogenization speed results in an increase in the work done on the system and thus a 
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decrease in particle size [63].  This concept is further explained below.  However, when a 
totally miscible solvent is used interfacial tension between the aqueous and organic 
phases does not play a role and as a result particle formation is not the result of the 
emulsion process, but rather of the polymer precipitating out of the solvent when added 
to the secondary aqueous phase.  Hence, homogenization speed should have little effect 
on particle size when completely miscible solvents are used. 
2.6.6 Interfacial Tension 
Interfacial tension results when two immiscible or only partially miscible phases 
are combined.   
nP,T,A  
G  
  
 (eq. 2.1) 
 = interfacial tension (Force/length) 
G = Gibb’s free energy 
A = Interface surface area 
The driving force in a closed system is to lower Gibb’s free energy, therefore, when two 
immiscible interfaces exist, the ways to minimize the Gibb’s free energy are to either 
lower the interfacial tension between the two phases or minimize the contact area 
between them. 
A    G  (eq. 2.2) 
The result is an attempt to minimize the contact area between these phases and any effort 
made to increase the contact area between these phases requires work.  In other words, in 
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order to increase the interface area, a certain amount of work must be added.  Thereby, 
the definition of interfacial tension is the work required to increase the contact surface 
between the two phases and represents the work over the interfacial contact area: 
dA
dW
  
 (eq. 2.3) 
Typically, interfacial tension is identified by gas and liquid systems, in which 
case, interfacial tension between the gas and liquid interface is referred to as surface 
tension.  In the case of a gas in liquid system (i.e. a bubble), then the work necessary to 
increase the bubble volume and hence increase the surface area of the gas-liquid interface 
is seen in the form of pressure.  This relation between pressure, volume and work is in the 
form of an energy balance and related by the following equation: 
dV P dW  (eq. 2.4) 
Figure 2.7 illustrates the pressure differential across a bubble of radius R and the change 
in pressure requirements to increase the bubble radius.  The increase in bubble area by an 
infinitesimal radius of R + dR is calculated as follows: 
RdR8  R - dR)  R (  4 dA 22  (eq. 2.5) 
This is related to the following change in free energy: 
RdR8 dA  dG  (eq. 2.6) 
The increase in bubble volume caused by the same infinitesimal increase in radius of R + 
dR is calculated as follows: 
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dRR4  R - dR)  R (  
3
4
  dV 233  (eq. 2.7) 
If energy is only put into the system in the form of work, then Gibb’s free energy is 
directly related to work and the equation for interfacial tension becomes that of equation 
2.3.  Therefore, interfacial tension is defined as follows: 
dA
PdV
  
dA
dW
  
dA
dG
   (eq. 2.8) 
Substituting in the values of dA (eq. 2.5) and dV (eq. 2.7) yields the following: 
R
2
  P  (eq. 2.9) 
This pressure differential is directly related to the work required to increase the surface 
area of a bubble.  In other words, decreasing particle radius requires either an increase in 
the pressure differential across a bubble or a decrease in the interfacial tension.  This 
pressure differential is more commonly referred to as Laplace pressure: 
P(Laplace) = 
R
2
  P  (eq. 2.10) 
These calculations relating bubble radius to interfacial tension and pressure differential 
were first derived by Evans et al [63]. 
In contrast to the system mention above, in an organic-aqueous emulsion system, 
the total volume of the organic phase is constant and equals the total volume of all the 
organic droplets: 
3r 
3
4
 droplets) (#  V
 (eq. 2.11)
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V = total volume of organic phase (ml) 
r = droplet radius 
Therefore, the total surface area of the organic aqueous interface is as follows: 
2r 4 droplets) (# SA  (eq. 2.12) 
SA = total surface area of the organic-aqueous interface 
Combining these equations to find the relationship between volume, surface area, and 
radius gives the following equation: 
SA
V 3
 r 
 (eq. 2.13)
 
During the secondary emulsion phase of the W/O/W method, when the organic droplets 
are formed, the solvent volume is constant.  Therefore, the only parameters that can 
change are droplet radius and surface area.  Radius and surface area are indirectly related 
to each other indicating that a decrease in droplet radius requires an increase in surface 
area of the solvent-aqueous interface.  Because the solvent-aqueous interface is 
unfavorable, increasing the contact surface area of this interface and hence decreasing 
droplet radius requires work.  For the W/O/W procedure utilized in this research, this 
work comes in the form of homogenization. 
2.6.7 Drug and Protein Incorporation into Particles 
 The W/O/W method has been used for the incorporation of hydrophilic proteins 
within the hydrophobic PLGA micro- and nano- particles for protein delivery [2, 54, 58, 
60, 65-77].  The W/O/W procedure is a physical entrapment method that can be applied 
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to a variety of proteins.  This is important because various types of proteins have shown 
benefits to nerve regeneration after SCI [9, 38].  Plus, injectable biodegradable particles 
that can provide a sustained active protein release have widespread potential use outside 
of just nerve regeneration.   
 Utilizing the W/O/W method properties that influence encapsulation efficiency 
include: physical and chemical properties of the polymers, solvent properties, polymer-
drug interactions, and properties of the aqueous phases [57].  Poor loading results when 
the drug leaves the organic phase (dispersed phase) and enters the secondary aqueous 
phase (continuous phase).  The properties mentioned above that influence encapsulation 
efficiency have either a direct or indirect effect on the drug going from the dispersed 
(organic) phase to the continuous phase.   
 One of the first formulation parameters of interest is the solubility of polymer in 
organic solvent.  The solubility of polymers in solvents has been shown to influence the 
particle solidification rate [78].  The solidification rate refers to the rate at which the 
organic solvent either evaporates or is completely dispersed in the continuous phase and 
leaves behind a ‘solid’ particle suspension.  The term solid is used loosely because the 
particles are still suspended in water and can still contain water molecules.  It just means 
that the polymer is no longer dissolved in a solvent because all the solvent has been 
removed.  In theory, once the particle is solidified, the particle composition is a 
condensed polymer matrix that can entrap the drug and limit or prevent drug diffusion 
into the continuous phase.  Therefore, polymer solubility effects solidification rate 
because it impacts how long the polymer can remain dissolved in the organic phase [57].  
Both solvent properties and polymer composition influence polymer solubility.  The 
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general concept is that the lower the polymer solubility in the organic phase, then the 
better the encapsulation efficiency because lower solubility relates to a higher 
solidification rate. 
 Another parameter of interest is the solubility and miscibility of the organic 
solvent in water.  Generally, solvents used for the W/O/W method have low solubility 
and miscibility in water.  However, in order for the particle to solidify, there has to be at 
least some solubility to allow for the solvent to enter the aqueous phase and evaporate.  
Therefore, increasing the miscibility of the solvent helps increase the rate at which the 
solvent enters the aqueous phase and increases the solidification rate.  This increase in 
miscibility has been shown to increase encapsulation efficiency [57, 79].  On the other 
hand, increasing solvent miscibility can increase the ability of the protein to diffuse out of 
the particle and into the aqueous phase, hence, decreasing loading efficiency [6].  
Ultimately, the effect of increasing solvent miscibility can have both a positive and 
negative influence on loading. 
 Increasing polymer concentration has been shown to increase loading [78, 80, 81].  
One explanation given is that faster precipitation of the polymer on the surface of the 
dispersed phase limits protein diffusion across the phase boundary [57, 80].  The second 
explanation is that the higher concentration of polymer in the dispersed phase limits the 
ability of the drug to diffuse out of the polymer droplets [57, 79]. 
 Polymer-drug interactions affect loading because the emulsion of the primary 
aqueous phase containing the drug and the organic phase containing the polymer force 
interaction between the two.  Any affinity between the drug and the polymer help 
increase loading because it reduces the likelihood that the drug will diffuse away from the 
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polymer and into the continuous phase.  In some cases, the hydrophobic interaction 
between protein and polymer can work to increase loading [57, 78].   
 Solubility of the drug in the continuous phase is important because if the drug has 
limited solubility in the continuous phase then there is less of a driving force for the drug 
to leave the organic/dispersion phase and enter the continuous/aqueous phase.  Methods 
to decrease the hydrophilicity of proteins by making protein-zinc water-insoluble 
complexes have been shown to increase the encapsulation efficiency of proteins [82].  
Other methods such as altering the pH of the continuous phase to decrease drug solubility 
have also worked to increase loading efficiency [83]. 
2.6.8 Protein Instability 
Two of the major challenges in developing protein-loaded particle delivery 
systems involve protein instability and incomplete release [57].  These same drawbacks 
apply when the W/O/W double emulsion solvent evaporation procedure is used for 
incorporating proteins.  One of the biggest disadvantages is protein instability caused 
mainly by the harsh preparation procedure and the acidic conditions within the particle 
microenvironment, ultimately resulting in incomplete protein release [65, 66, 84-87].  
The W/O/W double emulsion method is linked to protein denaturation primarily because 
of the presence of the aqueous-organic solvent interface [67, 68, 73, 87-91].  
Emulsification of an aqueous solution of a protein into a solution of PLGA dissolved in a 
hydrophobic solvent generates a large hydrophobic surface area linked to protein 
denaturation [87].  The shear stresses generated by increasing emulsification forces is 
thought to play a role in increasing protein denaturation, but mainly because of the 
increased contact surface area of the aqueous-organic solvent interface [86, 90-93].  
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Because this interface has been shown to play such a key role in protein denaturation, 
altering this interface is essential in maintaining protein activity.  This interface can be 
altered by either changing the hydrophobicity and miscibility of the solvent or by adding 
stabilizing agents.  The use of ethyl acetate as the solvent as opposed to the more 
hydrophobic dichloromethane (DCM) has been shown to induce less emulsification-
induced protein denaturation [67, 68, 86, 94].  The hypothesis is that increasing solvent 
miscibility (decreasing hydrophobicity) decreases interfacial tension and hence creates a 
less distinct interface between aqueous and organic phases.  Therefore, eliminating this 
interface all together and using a solvent such as acetone that is completely miscible in 
the aqueous phase should help to eliminate protein denaturation.  The problem associated 
with using less hydrophobic and more miscible solvents is poor encapsulation efficiency 
of proteins [56, 87, 95].  While altering the solvents may help reduce protein 
denaturation, it is essential that adequate protein loading can still be maintained. 
2.6.9 Initial Burst Release 
Although outside the scope of this work, another major challenge in the 
development of protein-encapsulated particle delivery systems is the initial burst release 
[57].  A lot of times with particle-based protein-delivery systems, the burst release results 
in an overdose of the protein, resulting in unwanted side effects and long-term 
complications [96].  Although there is the potential for unwanted side effects for an 
overdose of growth–factors [96], for this particular application an initial bolus delivery is 
desired to condition the spinal tissue so that following the initial injection, a lower, more 
sustained delivery of therapeutic proteins is ideal.   
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Despite the acceptability of an initial burst release for this particular application, it 
is important to address some of the major causes of the burst release to open the door for 
tailoring protein loaded particles for alternative applications where a burst release may be 
detrimental.  The cause of the initial burst release is primarily linked to the release of 
protein embedded in the surface layer [57, 80, 97-99].  This surface layer can potentially 
extend throughout the polymer matrix through pores and cracks that form during the 
preparation process [100, 101]. 
If the burst release is linked to surface associated proteins and the formation of 
pores increase the surface area that is exposed to the release medium, then factors 
influencing pore formation and water uptake also influence the burst release.  These 
parameters include: polymer molecular weight, polymer concentration, hydrophilicity of 
polymer, drug loading and composition of continuous phase (i.e. outer aqueous phase) 
[57].  Low polymer molecular weight is linked to a high burst release because the higher 
polymer solubility in the organic solvent results in slower solidification and thus, 
increased porosity [98, 102-104].  In addition, lower molecular weight polymers are 
attributed to smaller particles [100].  Smaller particles are attributed to a higher burst 
release because of the increased surface area for drug diffusion [57].  Low polymer 
concentration in the organic phase also results in a high burst release because of high 
internal particle porosity [100].  The polymer hydrophilicity impacts burst release 
because it affects how quickly the particles will uptake water.  In general, increasing the 
polymer hydrophilicity increases water uptake which increases the burst release.  For 
example, when dealing with PLGA particles, increasing the ratio of glycolide to lactide 
increases the hydrophilicity of the particle (because glycolide lacks the –CH3 group and 
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is more hydrophilic) and thus increases the burst release [105].  A ratio of 50/50 of 
glycolide/lactide is considered a relatively high glycolide ratio and is used when a high 
burst release (and increased water uptake resulting in accelerated degradation) is 
acceptable [98].  Increased protein loading is also directly related to increased burst 
release [97, 98, 106].  This is potentially linked to the creation of channels caused by the 
elution of proteins towards the particle surface during preparation or towards a higher 
concentration gradient between the entrapped protein and the release medium [100, 106].  
Finally, the composition of the continuous phase is related to the burst release for several 
proposed reasons.  Increasing the surfactant, (poly (vinyl alcohol)) (PVA), concentration 
has been shown to decrease the burst release, potentially because the high PVA 
concentration increases the viscosity of the continuous phase and slows drug migration 
out of the internal aqueous phase [100].  The addition of NaCl in the continuous phase 
has resulted in a decrease in burst release [107].  The NaCl increases the osmotic pressure 
across the organic phase which limits the influx from the continuous phase into the 
primary aqueous phase (dispersed phase) and thus, reduces the formation of water 
channels [57]. 
2.6.10 Drying Conditions and Impact on Release 
In addition to the preparation conditions mentioned above, post-particle 
preparation storage and drying steps can affect the drug distribution in the polymer 
matrix [57, 101].  Freeze-drying or lyophilization is the process by which the particles are 
frozen after the final wash steps and then dried under vacuum so that the ice crystals 
sublimate to water vapor.  This is an effective method because particles that have been 
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dried are easier to store and work with because the exact particle amounts can be weighed 
without considering the water weight percentage. 
Freeze-drying is preferred to convection drying methods of water filled particles, 
because the water flows to the particle surface prior to evaporation.  This diffusion of 
water to the surface also enables the diffusion of drug to the surface, causing more 
surface associated drug, and thus, more of a burst release [57].  To prevent the diffusion 
of drug to the surface during the drying phase, the water content within the particle is 
frozen and dried by sublimation.  While the drug molecules are locked in place during the 
freeze-drying process, ice crystals still need to escape out of the polymer matrix.  The 
concern is that freeze-dried particles will be more porous due to the escaping ice crystals 
and that the increased porosity will increase the burst release.  These concerns are 
addressed in Chapter 4 of this thesis.  
2.6.11 Additives 
2.6.11.1 Sucrose Acetate Isobutyrate (SAIB) 
Sucrose acetate isobutyrate (SAIB) is an additive that when added to the organic 
phase can increase loading.  It was first used by Lee et al. in PLGA microspheres for not 
only improved loading, but also for slowing PLGA degradation and creating a linear 
(zero order) release profile of protein [108].  It was believed to improve loading and slow 
protein release by increasing the viscosity within the PLGA particles [108].   Lee et al. 
used the SAIB additive in micron size particles on the order of 24-30 m.  It is unclear if 
SAIB as an additive has similar benefits in submicron sized particles.  The increase in 
surface area to volume ratio with a decrease in particle size may result in differences with 
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the burst release because burst release is primarily related to the release of surface 
associated proteins [57].   
2.6.11.2 Bovine Serum Albumin (BSA) 
One way to help limit protein denaturation is the use of additives in the aqueous 
phase.  Because of the damaging organic-aqueous interface established during the 
primary emulsion various additives have been used to occupy this interface and both limit 
access to the protein of interest and stabilize the primary emulsion.  One of those 
additives shown to help limit protein denaturation and help stabilize the organic-aqueous 
interface is bovine serum albumin (BSA) [74, 109].  In addition to protein damage caused 
by the first emulsion step, drying the particles by lyophilization and the acidic 
microenvironment created during particle degradation are other potential areas for protein 
damage and ultimately, incomplete release of active protein [86].  Denaturation and 
aggregation are common effects of lyophilization on protein [110, 111], however PLGA-
encapsulation of proteins has been shown to offer protection from these effects [67, 68, 
86, 89, 112, 113].  During release protein instability results from the acidic 
microenvironment within the particles created by the acidic PLGA degradation products 
[73, 86, 92, 114-117].  BSA encapsulated with the protein of interest can help limit 
protein degradation and incomplete protein release by acting as a proton scavenger and 
by competitive adsorption to the PLGA [73, 116].  Part of this work evaluates the 
benefits of BSA as a stabilizing additive for protecting protein from the harmful effects of 
emulsion and the acidic microenvironment within a degrading PLGA particle. 
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2.6.12 Release Characteristics 
Protein release from PLGA particles is generally characterized as having a tri-
phasic release profile.  Step 1: Burst release of surface associated protein via desorption 
of protein.  Step 2: Diffusion release of protein within the particle.  Step 3: Particle 
degradation resulting in increased particle diffusion out of the particle.  An illustration of 
tri-phasic release is shown in Figure 2.8. 
Step 1: Burst release (desorption) 
d
s
d
d
s
Ck
dt
dC
 (eq. 2.14) 
C
s
d = Concentration of protein at particle surface ( g/ml) 
kd = desorption rate constant (1/t) 
t = time (s) 
Equation 2.14 has the following solution 
t-k
d
s
d
s d(0)eC  (t)C (eq. 2.15) 
Assume volume at the particle surface is constant then 
tk- de  
m(0)
m(t)
 (eq. 2.16) 
m(0) = amount of protein at particle surface at time zero 
m(t) = amount of protein at particle surface time (t)
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Step 2: Protein diffusion 
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 (eq. 2.17)
 
DAB = Coefficient of diffusion of protein in particle (cm
2
/s) 
cA = Concentration of protein inside particle ( g/ml) 
r = particle radius (cm) 
Assumptions: radial symmetry, dilute solutions of the protein dissolved in the gel matrix, 
and no degradation of the protein inside the particle. 
Boundary conditions: 
0  t 0,  c  c R, r 
0  t 0, 
r
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 0, r 
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At the center of the particle where the flux NA(0,t) is equal to zero.  The initial condition: 
R r   0 ,c  c 0, t AoA  
Analytical solution: 
222
 AB t/rnD-
1n
22
Ao
A e
n
16
  
m
(t)m
 (eq. 2.18) 
 
Step 3: Particle degradation 
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As the particles degrade, the PLGA matrix that limits the diffusion of protein out of the 
particles begins to loosen and the result is a change in the coefficient of diffusion.  
n degradatio    DAB f  (eq. 2.19) 
Because the matrix is degrading, protein should diffuse through the matrix more readily, 
resulting in an increasing diffusion coefficient.  PLGA is generally regarded as a bulk 
eroding polymer [53], meaning that water is taken up by the PLGA particles much faster 
than the degradation of the polymer [118].  Thus, the entire particle is wetted and the 
polymer chains hydrolyze throughout the entire system [118].  Faisant et. al. linked the 
decrease in molecular weight to a degradation rate constant of PLGA [118]: 
t)(-k e 78.4  Mw(t) degr  (eq. 2.20)
 
Mw(t) = Change in PLGA molecular weight with time 
kdegr = First order degradation rate constant of the polymer 
Therefore, because the degradation of PLGA is related to the ability of drug to diffuse out 
of the matrix, the change in molecular weight should be inversely related to the change in 
the diffusion coefficient: 
(t)D
1
  Mw(t)
AB
 (eq. 2.21) 
 
Ultimately, the change in the diffusion coefficient should be proportional to a similar 
scaling parameter as the change in molecular weight and this scaling parameter is related 
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to the polymer degradation.  The diffusion coefficient as a function of time should carry 
the following relationship: 
 t)(k e  a - (t)D degr - DAB  (eq. 2.22)
 
a = constant 
kD-degr = degradation rate constant of diffusion 
Constants and scaling parameters utilizing this mathematical model are calculated using 
the release data generated in Chapter 4. 
2.7 Particle Biocompatibility 
 While the use of PLGA is accepted as a biocompatible polymer because of its 
degradation byproducts, the immune response when formed into particles and injected 
directly into spinal tissue is not known.  Preliminary studies sought to answer this 
question and the results were cause for concern.  Biocompatibility and biodistribution 
studies were performed by the injection of three different size particles made in DCM, 
ethyl acetate and acetone with average diameters of 535.1 ± 124.2 nm, 260.5 ± 41.8 nm 
and 115.6 ± 6.4 nm, respectively.  The particles were loaded with a safe red fluorescent 
dye, PKH26, for visualization (Fig. 2.9a).  The particles were resuspended in PBS at a 
concentration of 0.4 mg/ml and a stereotaxic injection setup was used to delivery 1 l of 
the particle suspension at both the injured and non-injured sides of the spinal cord (Fig. 
2.9c).  The injury was caused by siphoning away a tissue section.  Eight days after the 
surgery, the rats were sacrificed and the spinal cords removed for cryosectioning.  Tissue 
samples were stained for macrophages (anti-monocytes/macrophages (ED1)) and scar 
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formation (anti-Glial Fibrillary Acidic Protein (GFAP)).  Secondary antibodies for 
macrophages were green and secondary antibodies for scar tissue were blue.  Typically, 
the macrophage response is localized to the injury sight, but in the case of this particle 
injection study, macrophages and areas of tissue loss are seen away from the injury sight.  
A minimal macrophage response from the act of injecting is also possible, but nowhere 
near the level of the immune response that was observed.  Indication of the heightened 
macrophages response is shown in Figure 2.9b.  The potential causes for this immune 
response include particle sterility, residual surfactant (Poly (vinyl alcohol)), opsonin 
surface adsorption and particle cytotoxicity.  Additional work seeks to address these 
potential causes. 
2.7.1 Particle Sterilization and Plasma Treatment 
Current and more traditional sterilization methods involve exposure to ethylene 
oxide, chlorine, ozone, gamma radiation or heat [119, 120].  When certain polymers are 
sterilized utilizing these methods the results are unfavorable changes in physical, 
chemical and mechanical properties [120].  One of the most promising sterilization 
methods for the surface treatment of polymers is non-thermal (< 50˚C) atmospheric 
pressure plasma [120]. While the mechanism of non-thermal plasma sterilization is not 
entirely known, it has been shown safe enough for application directly to human tissue 
[119, 121].  Plasma discharge generates reactive species such as ozone (O3), peroxides, 
OH radicals, etc. that can react with and destroy bacteria [119, 121, 122].  Since the 
reactive species generated can react with organic materials such as protein, there has been 
evidence of plasma treatment causing significant protein activity loss [123].  Therefore, a 
plasma treatment method was developed so that the protein loaded particles would not 
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have to come in to direct contact with the plasma discharge.  The specific type of plasma 
sterilization used in this work utilizes an electrode to discharge non-thermal plasma 
through water or PBS contained in a grounded well (Fig. 2.10).  This treated water or 
PBS is then used as the sterilizing agent.  While indirect exposure to plasma is preferred 
to reduce damage to the particles and the protein, it is also less effective as a sterilizing 
agent [124]. This decontamination method has never been attempted with either PLGA 
particles or protein loaded PLGA particles so the sterilization effectiveness and effects on 
both the particles and the protein are unknown.  Because the particles can be prepared in 
a controlled laboratory setting bacterial inactivation is considered adequate when 
complete inactivation is achieved after exposure to a low bacterial load of E. coli at a 
concentration of 10
3
 CFU/ml.   
2.7.2 Polyvinyl Alcohol (PVA) 
 PLGA particle formation via the W/O/W double emulsion technique requires a 
surfactant to limit the interfacial tension between the organic and exterior aqueous phases 
to allow the organic phase to form individual droplets and not agglomerate.  PVA is one 
of the most widely used polymeric surfactants for making particles with the W/O/W 
double emulsion method.  While attempts are made to wash PVA from the particle 
surface, studies have shown that washing does not remove all the PVA because PVA 
forms an interconnected polymer network at the particle surface [125, 126].  While PVA 
scaffolds are continuously used as a biomaterial [127-131], there remain concerns over 
the safety of PVA molecules [132-134].  Safety concerns are the result of organ lesions 
and hypertension in rats observed with repeated intravenous or subcutaneous 
administration of PVA [132-134].  Repeated intravenous or subcutaneous administration 
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in dogs has resulted in central nervous system depression followed by anemia [132-134].  
While the administered dose of PVA delivered for these safety studies exceeds the 
amount of residual PVA that would remain in PLGA particles there is still the potential 
that the impact of low amounts of PVA delivered directly to injured spinal tissue could be 
negative.  Studies have also shown that a residual amount of PVA on the particles surface 
can interfere with PLGA particle surface characteristics [125]. 
 Therefore, because of safety concerns and the impact on surface characteristics 
there is motivation to make particles free of surfactant.  Gref et. al. utilized 0.1 wt% of 
sodium cholate as a surfactant for PLA particles made with DCM as the solvent utilizing 
the W/O/W double emulsion method [135].  The result was particles that contained no 
trace of surfactant on the surface.  This was confirmed by surface analysis [135, 136].  In 
order to keep the organic phase from agglomerating and allowing it to form individual 
droplets, Greg et. al. utilized sonication to disperse the organic phase in the secondary 
aqueous phase.  Sonication provides a higher energy input into the system then 
homogenization and allows for a monodisperse distribution of nanoparticles [135].  This 
is important because similar size particles are less likely to undergo a phenomenon 
known as ostwald ripening [137].  During the evaporation step of particle formation 
(where little energy is being put into the system), ostwald ripening involves the diffusion 
of a smaller particle into a larger particle droplet.  Typically, surfactant can prevent this 
from happening, but with a low amount of surfactant, this can be prevented by having 
particles of similar size.  The other way to prevent this from happening is to utilize a 
precipitation method to make monodisperse particles where the organic phase is 
completely miscible and is already dispersed within the aqueous phase. 
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2.7.3 Protein Adsorption on Particles 
Because the inflated macrophage response was seen only 1 week after particle 
injection into spinal tissue, biocompatibility concerns are those which may trigger a 
Phase I inflammatory response. The Phase I inflammatory response happens in the first 
one to two weeks and involves acute or chronic inflammation invoking an influx of 
macrophages.  Protein adsorption on biomaterials is a concern because it is one of the key 
mechanisms that determine the body’s inflammatory response to the material.  Molecules 
that target foreign bodies in order to elicit an immune response are referred to as 
opsonins.   Examples of opsonins in the body include the antigens, IgM and IgG; 
components of the compliment system, C3b and C4b; and mannose-binding lectin.  When 
utilizing particles as a biomaterial, biocompatibility concerns result when opsonins 
adsorb on the particle surface and initiate an immune response designed to recognize the 
particle as a foreign substance and clear it from the body.  Particle clearance is primarily 
the result of the antigen, Immunoglobulin G (IgG) (Fig. 2.11) because IgG has receptors 
that initiate uptake by macrophages via phagocytosis.  If not for IgG, then foreign 
substances such as bacteria would remain undetected by macrophages because both the 
bacteria and macrophage have a negative surface charge and would normally repel one 
another.  However, the antigen binding sights on IgG end in the positive charged amine 
groups which can adsorb to the negative charged bacteria.  Macrophages are coated with 
antibodies that recognize antigens such as IgG and ingest the substance with the IgG 
attached. 
Because the first step for macrophage recognition of particles is the opsonization 
(adsorption) of opsonin proteins to the particle surface [5, 25, 28, 138] the goal is to limit 
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this adsorption.  Research has shown that particles with highly hydrophobic surfaces 
(such as PLGA surfaces) have a very high affinity to the opsonic proteins [138-140]. 
Enhanced opsonization is seen in hydrophobic, negative nanoparticles versus hydrophilic, 
neutral nanoparticles [57, 141-143].  The exact mechanism for opsonin adsorption is 
unknown and it is unclear whether hydrophobicity or surface charge plays a more 
dominant role in protein adsorption, so research has been done to look exclusively at 
particle zeta potential [144]. This research showed that making particles more negative 
resulted in decreased protein adsorption [144].   
2.7.4 Particle Surface Modification 
Particle surface characteristics are critical when dealing with implantable particle 
based delivery systems because of the high surface area to volume ratio.  The most tested 
way to increase surface hydrophilicity, neutralize surface charge and ultimately limit 
opsonin adsorption and macrophage signaling and uptake is the attachment of 
poly(ethylene-glycol) (PEG) to the particle surface [5, 57, 58, 135, 145-148].  PEG can 
either be conjugated to PLGA prior to particle formation or be conjugated to PLGA after 
particle formation.  Therefore, in order to reduce opsonin absorption to the PLGA 
particles, PLGA will be conjugated to PEG with two alternative reactions.  For 
conjugation of PEG to the particle surface post fabrication, the PLGA particles will be 
PEGylated by an EDC coupling reaction that conjugates the carboxyl end group of PLGA 
to the amine end group of diamine PEG (Fig. 2.12).  For conjugation of PEG to PLGA 
prior to particle fabrication, methoxy poly(ethylene glycol) (mPEG) will be polymerized 
to form mPEG-PLGA by a ring-opening melt polymerization reaction (Fig 2.13).  In this 
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case, the hydroxyl group of mPEG initiates the reaction and begins the polymerization of 
the lactide and glycolide monomers. 
Because increasing particle hydrophilicity has also been shown to decrease 
phagocytosis [149], an alternative method for altering the hydrophilicity of the particle 
surface is by plasma treatment to create peroxide, hydroxyl and carbonyl groups [150-
153]. 
2.7.5 Particle Cytotoxicity 
 Although PLGA is an FDA approved polymer for use as a biomaterial, there 
remains cytotoxicity concerns when PLGA is delivered in the form of micro- and nano-
particles.  There is a widespread concern over nanoparticles that are less than 100 nm 
because of their ease of internalization into tissue, cells and organelles.  Concerns over 
cytotoxic surface properties are enhanced with smaller particles because of the higher 
surface area available to interact with cells.  However, because a lot of particles used for 
this study are within the 0.1 to 1.0 m diameter range, there is no clear link between 
particles in this size range and cytotoxicity.  Because particles are directly injected into 
spinal tissue, cytotoxicity concerns are directly related to potential cell death and cell 
damage.  Unfortunately, there is limited work relating particle size to cell death.  
Therefore, cytotoxicity studies are required that involve the direct interaction of particles 
within the size range of 0.1 to 1.0 m with cells.  The particles’ effect on cells is a 
concern because cell death caused by foreign material stimulates and immune response 
[1]. 
Other cytotoxicity concerns are related to the potential of residual solvent or pH 
changes caused by the degradation bi-products of PLGA.  While it is unlikely that any 
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solvent remains associated with the particles because of the preparation conditions that 
include evaporation, washing and freeze-drying, it cannot be ruled out as a concern.  
Also, because preliminary studies showed an immune response after only one week of 
subcutaneous injection of PLGA particles it is doubtful that degrading PLGA was the 
cause.  This is because only one week is well below the degradation time specified by the 
manufacturer.  The degradation time specified by the manufacturer is around one month.  
Reactants used for PEGylation (i.e. N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC)), solvents used to purify the mPEG-PLGA reaction (diethyl ether), 
and byproducts of plasma treatment (i.e. ozone, free radicals, etc.) raise cytotoxicity 
concerns if not properly neutralized or washed off of particles. 
2.8 Other Potential Applications 
Aside from injecting protein loaded particles directly into spinal tissue, the use of 
protein loaded biodegradable nanoparticles has widespread potential in a multitude of 
other applications.  The practicality of these applications is increased by overcoming the 
various drawbacks associated with the use of biodegradable particles for protein delivery.  
These drawbacks include insufficient protein loading, lack of protein stability, incomplete 
active protein release and particle biocompatibility.  Addressing and overcoming all of 
these obstacles are the basis of this research.  Thus by using a physical encapsulation 
method that can incorporate a variety of proteins and by changing preparation parameters 
to increase protein stability, improve loading,  increase active protein release and enhance 
particle biocompatibility the doors are open to many other applications.  These 
applications include, but are not limited to transdermal delivery, polymeric scaffolds and 
oral delivery. 
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2.9 Protein Therapeutics 
Protein therapeutics refers to the use of proteins for medical treatments.  Although 
this field began over 25 years ago by the development of insulin, the use of protein 
therapeutics is still in the early stages of growth.  Today there are over 130 protein 
therapeutics currently used for medicinal applications with many more in development 
[154].  Protein therapeutics have several advantages over small-molecule drugs such as: 
highly specific set of functions; less chance to cause adverse effects; well tolerated and 
less likely to elicit an immune response; protein replacement therapy for genetic 
disorders; and potentially faster FDA approval time [154].  Some of the current 
challenges for protein therapeutics are related to protein solubility, route of 
administration, stability and distribution [154-156].  By incorporating protein 
therapeutics inside of a nanoparticle carrier system capable of sustained delivery, the 
pharmacokinetics and distribution properties can take on that of the nanoparticle carrier 
and potentially reduce a lot of the challenges related to solubility, administration, stability 
and distribution. 
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Figure 2.1: Spinal cord anatomy.  Cross-section illustrates nerve fibers and axonal tracts. 
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Figure 2.2: Spinal cord injury.  Image indicates the legion created by original damage followed 
by secondary damage and the creation of a fluid-filled cyst.  Glial scar formation works to isolate 
the injured area. [wingsforlife.com] 
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Figure 2.3: (A) Degradation of PLGA through hydrolysis (B) Lactide and glycolide chemical 
structures.   
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Figure 2.4: Protein structures.  
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Figure 2.5: W/O/W double emulsion solvent evaporation procedure with immiscible and partially 
miscible solvents. 
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Figure 2.6: W/O/W double emulsion solvent evaporation procedure with miscible solvents. 
  
Solvent + PBS + 
Surfactant 
Protein Polymer 
Solvent 
‘Solid’particles 
with entrapped 
protein 
44 
 
 
Table 2.1: Solubility and Interfacial Tension Values 
Solvent 
Solubility in Water 
(at 20˚C) 
Organic-water interfacial 
tension 
(mN/m) 
DCM 1.6% 28.3 
Ethyl Acetate 8.7% 6.8 
Acetone Miscible in all proportions --- 
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Figure 2.7:  Force required to blow a bubble in a liquid. [63] 
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Figure 2.8: Tri-phasic protein release. 
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(A)  
(B) (C) 
 
Figure 2.9: (A) Fluoresced PLGA particles used for injection.  (B) Tissue section indicating 
heightened macrophage response.  Red indicates particles and green indicates macrophages.  (C) 
Example cross-section indicating injection sight, injury sight and the area where the tissue loss 
and macrophage response was noticed.  Scale bar 50 m. 
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Figure 2.10:  Plasma discharge into 2 ml grounded well.  
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Figure 2.11: Immunoglobulin G (IgG) structure. [wikepeida.com] 
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Figure 2.12:  EDC/sulfo-NHS particle PEGylation.   
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Figure 2.13: Ring-opening polymerization. 
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3. Chapter 3:  Analysis of Preparation Conditions on Particle Size, Size 
Distribution and Loading 
3.1 Introduction 
 PLGA nano/micro particles have enormous potential as a sustained protein 
delivery device for a variety of applications.  The first attempt at injecting nanoparticles 
directly into spinal tissue was performed by Wang et. al. [2].  Because this concept of 
injecting particles into spinal tissue was new, Wang et. al. did not specify an ideal particle 
size.  Therefore, with this application and most potential applications the ideal particle 
size is unknown.  It is because of these unknown size requirements that the ability to 
make particles with a variable size range while maintaining adequate protein loading is 
required.  Wang et. al. investigated the biodistribution of particles (20 nm and 100 nm) 
injected into spinal tissue [2].  Results indicated nanoparticles with a size of 20 nm could 
be easily taken up by neurons, while the 100 nm nanoparticles were mainly restricted to 
the injection site or possibly transported in the central canal [2].  Because the desire is for 
the particles to stay localized to the injection site, a particle minimum diameter of 100 nm 
was chosen.  While there has been no work performed to establish a maximum particle 
diameter, a maximum particle diameter of 1 micron was chosen for the following 
reasons:  ease of injection, to minimize damage upon injection and to minimize 
interference with growing axons.  Larger particles (> 1 m diameter) have also been 
shown to induce a greater immune response and increase uptake by phagocytosis [157, 
158]. 
 The goal of Chapters 3 and 4 is to systematically evaluate numerous factors that 
could impact the effectiveness of protein loaded PLGA nanoparticles as a delivery system 
for proteins into spinal tissue.  The effects of solvent miscibility (dichloromethane 
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(DCM), ethyl acetate, acetone), homogenization speed (10-25 krpm), PLGA 
concentration (10-30 mg/ml) and additives in both the organic (Sucrose Acetate 
Isobutyrate (SAIB)) and aqueous (Bovine Serum Albumin (BSA)) phases on particle 
size, protein loading, protein delivery and protein activity are assessed.  In Chapter 3, 
particle size, size distribution and protein loading are evaluated, while Chapter 4 assesses 
protein activity and active protein release. 
 There are various thermodynamic principles that govern the relationships between 
particle size, interfacial tension and energy input into an emulsion system.  Size results 
are evaluated utilizing these thermodynamic relationships.   
3.2 Experimental Section  
3.2.1 Materials 
 Poly(lactide-co-glycolide) (PLGA, average molecular weight (MW) 18 kDa, 
copolymer ratio 50:50) (Figure 1) was purchased from Lakeshore Biomaterials 
(Birmingham, AL).  Lysozyme (MW 14.3 kDa, Activity 63,628 Units/mg protein), 
sucrose acetate isobutyrate (SAIB, MW 846.91 Da) and Dulbecco’s Phosphate Buffered 
Saline (PBS, pH 7.4, KCl – 0.2 g/L, KH2PO4 – 0.2 g/L, NaCl – 8.0 g/L and Na2HPO4 – 
1.15 g/L) were purchased from Sigma-Aldrich (St. Louis, MO).  Poly(vinyl alcohol) 
(PVA, average MW 25 kDa, 88% hydrolyzed) was purchased from Polysciences, Inc. 
(Warrington, PA).  All organic solvents were of HPLC grade and purchased from Sigma-
Aldrich (St. Louis, MO). 
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3.2.2 Methods 
3.2.2.1 Particle Preparation 
Particles were prepared by a W/O/W double emulsion solvent evaporation 
procedure.  Phase volume ratios and surfactant (PVA) type and concentrations 
established by Dziubla et. al. were utilized [93].  The first water-oil phase contained 250 
l of an aqueous solution consisting of lysozyme (5 mg/ml) in PBS plus 2.5 ml of an 
organic solution consisting of PLGA (10, 20, 25 or 30 mg/ml) or PLGA + SAIB (20 + 5 
mg/ml, respectively) in DCM, ethyl acetate or acetone.  The first water-oil phase was 
homogenized (Polytron® System PT3100 homogenizer with PT-DA 3007/2EC 
dispersing aggregate, Kinematic, Inc, Bohemia, NY) for 1 minute at speeds 10,000, 
15,000, 20,000 or 25,000 rpm.  The first emulsion was then removed and slowly pipetted 
into 12.5 ml of 2 (w/v) % PVA kept at 4˚C while being homogenized at the same speed 
as the first emulsion.  The second emulsion was homogenized for two minutes.  To allow 
for solvent removal, the second emulsion was then added to 25 ml of 2 (w/v) % PVA and 
allowed to stir overnight at 350 rpm.   Particles were then collected by centrifuging at 
15,000 G for 30 to 50 minutes.  The particles obtained were washed twice in deionized 
(DI) water and centrifuged each time to collect.  After the final centrifuge, the particles 
were resuspended in 1 or 2 ml of DI water and flash froze in liquid nitrogen prior to 
freeze drying.  To avoid PLGA degradation during storage, freeze-dried samples were 
stored under desiccant at -20˚C until use. 
3.2.2.2 Effect of Solvent Miscibility on Particle Size and Size Distribution 
Particles were prepared according to the particle preparation method mentioned 
above, with the following exceptions.  The organic phase consisted of various mixtures of 
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DCM and acetone.  The weight percent ratios of DCM to acetone utilized were 100, 80, 
60, 40, 20, and 0 weight %.  Exact volume ratios are listed in Table 3.1.  Homogenization 
speed was maintained at 15,000 rpm and the PLGA concentration in the organic phase 
was 25 mg/ml.  The primary aqueous phase consisted of only PBS. 
3.2.2.3 Particle Morphology and Size Analyses 
After the final wash, the supernatant was removed and the particles were 
resuspended in 1 or 2 ml of DI water.  A small sample of suspended particles was 
removed and diluted to an approximate concentration of 1 mg/ml.  40 l of this diluted 
sample was then pipetted onto an SEM stub and flash froze in liquid nitrogen.  The 
sample was then freeze-dried and sputter coated with a platinum/palladium mixture prior 
to imaging.  In order to eliminate deviations caused by polydisperse samples when 
measured indirectly by photon correlation spectroscopy, particle size of the dried samples 
was determined directly using scanning electron microscopy (SEM) (Zeiss Supra 50VP 
operated at 2 kV) and Image J software.  Image magnification was varied to allow for 
measurement of the smallest particles while providing a suitable number of particles per 
screen shot for counting.  Samples were prepared in triplicate and 200 particles were 
counted per sample.  For each set of 200 particles counted, the average particle diameter 
was calculated as a number average (eq. 3.1) and particle size deviation was calculated as 
a standard deviation (eq. 3.2).  These values were used to calculate the polydispersity 
index (eq. 3.3). 
i
i
i
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d  diameter particle average  (3.1) 
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d = particle diameter 
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3.2.2.4 Lysozyme Loading 
Glass vials used for loading studies were treated with Sigmacote® (Sigma 
Aldrich, St. Louis, MO) to prevent lysozyme adsorption on the glass wall.  Dry particles 
were resuspended in 0.5 M NaOH (10 mg/ml) and allowed to stir overnight until totally 
degraded.  The solution was then neutralized with an equal volume of 0.5 M HCl.  
Samples were synthesized in triplicate. Blank particles without protein were also 
synthesized and subjected to the same degradation and assay conditions to account for 
any absorbance caused by the degraded polymer.  Standards were subjected to the same 
treatment and protein concentration was determined using the BCA™ assay.  Loading 
was calculated in terms of loading efficiency (eq. 3.4) and the protein weight percent of 
the particles (eq. 3.5).  Loading efficiency was determined for particles loaded only with 
lysozyme and not for particles loaded with both lysozyme and BSA because the BCA™ 
assay cannot distinguish between the two proteins. 
57 
 
Particlesin  Lysozyme of Mass lTheoretica Total
Particlesin  Lysozyme of Mass
 x 100  (%)Efficiency Loading   (3.4) 
Lysozyme  Particles of Mass
Lysozyme of Mass
 x 100  %Weight  (3.5) 
3.2.2.5 Statistical Analysis 
 The results are presented as mean ± standard deviation.  Significant trends in 
group data were determined using two factor analysis of variance (ANOVA).  Statistical 
significance was considered at p < 0.05. 
3.3 Results 
3.3.1 Particle Size and Distribution 
All particle samples were freeze-dried and imaged under SEM post preparation.  
Examples of particle images are shown in Figure 3.1.  Particle morphology is 
representative of dried particles with no visible pores.  Image J software was used to 
analyze the SEM images and physically measure the particle diameters.  As illustrated in 
Figure 3.2 the effects of homogenization speed and PLGA concentration on average 
particle diameter (eq. 3.1) and diameter size deviation (eq. 3.2) using three different 
solvents with varying miscibility was determined.  Particle size and deviation decreased 
with increasing solvent miscibility.  Particles made in DCM had the largest average 
diameters and deviation, with particles made in ethyl acetate the next highest and 
particles made in acetone were the smallest and most homogeneous.  For the immiscible 
and partially miscible solvents, DCM and ethyl acetate, respectively, increasing 
homogenization speed resulted in decreased particle size and deviation as seen in Figure 
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3.2a and 3.2b (p < 0.01).  For the miscible solvent, acetone, increasing homogenization 
speed had no significant effect (p > 0.05) on particle size or deviation as seen in Figure 
3.2a and 3.2b.  Increasing PLGA concentration showed an increase in particle size and 
deviation when ethyl acetate and acetone were used as the solvents (p < 0.01, except for 
average diameter in ethyl acetate, p <0.05), but had no significant effect (p > 0.05) on 
size or deviation when DCM was used as the solvent.  This data is illustrated in Figures 
3.2c and 3.2d. 
The polydispersity index (PDI) (eq. 3.3) is illustrated in Figures 3.3a and 3.3b.   
All particles made with DCM as the solvent and particles made at slower homogenization 
speeds (10 and 15krpm) with ethyl acetate as the solvent had PDI values greater than one.  
Values greater than one indicate not only very polydisperse samples, but Non-Gaussian 
particle distribution.  For immiscible and partially miscible solvents, DCM and ethyl 
acetate, increasing homogenization speed seems to decrease PDI.  However, for the 
completely miscible solvent, acetone, homogenization speed has no noticeable effect.  
For miscible and partially miscible solvents, acetone and ethyl acetate, increasing PLGA 
concentration seems to increase PDI, but there is no clear trend between PDI and PLGA 
concentration when DCM is used as the solvent. 
Illustrating the data in histograms gives a clear indication of the particle size 
distribution as seen in Figure 3.4.  In Figure 3.4, all the x-axis is unchanged to give a 
clear distinction between particle distributions when different solvents are used. 
Histogram data also illustrates how particle mean may not always be representative of the 
number of particles at a particular size range, particularly for positively skewed data.  
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This is further indication of a Non-Gaussian particle distribution, primarily for particles 
made with DCM as the solvent. 
Particles made by varying the solvent ratios of acetone and DCM in the organic 
phase showed a trend of increasing particle size with an increase in the amount of DCM 
(Fig 3.5a).  This trend was fairly linear; however, there was an outlier at the 20 (w/w) % 
DCM/Acetone ratio that skewed statistical evaluation.  The particle size deviation 
followed a similar trend indicating an increasing size distribution with an increase in the 
amount of DCM (Fig 3.5b).  SEM images of particles made by varying the DCM and 
acetone ratio are shown in Figure 3.6. 
3.3.2 Lysozyme Loading 
The amount of lysozyme loaded into particles was determined by completely 
degrading the particles in a basic solution and then using a protein concentration assay to 
determine the amount in the neutralized solution.  Loading efficiency represents the ratio 
of the actual amount of protein entrapped and the theoretical amount of protein that could 
be entrapped.  Weight percentage indicates how much of the particle weight is composed 
of the protein.  In general, increasing PLGA concentration increased loading efficiency, 
but for acetone and DCM the loading efficiency was the highest at a concentration of 25 
mg/ml as seen in Figure 3.7a (p < 0.01, except for loading efficiency of particles made in 
ethyl acetate, p < 0.05).  PLGA concentration had the reverse effect on weight percent 
meaning that increasing the PLGA concentration decreased the protein weight percentage 
of the particle as seen in Figure 3.7b (p < 0.01).  Loading efficiency and protein weight 
percentage increased with increasing homogenization speed for the partially miscible 
solvent ethyl acetate (p < 0.05), but loading efficiency and weight percentage decreased 
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with increasing homogenization speed for the totally miscible solvent acetone (p < 0.01) 
as seen in Figure 3.8a and 3.8b.  There was no significant difference (p > 0.05) between 
homogenization speed and loading when DCM was used as the solvent. 
When SAIB was included with PLGA in the organic phase, the result was an 
increase in loading efficiency and weight percentage for all solvents used as shown in 
Table 3.2. 
3.4 Discussion 
3.4.1 Particle Size and Distribution 
It is suitable to generate a particle size range because it is yet to be determined 
which particle size is best for injection directly into tissue.  Smaller particles (i.e. 20 nm 
diameter) are subject to uptake by neurons [2], while larger particles (> 1 m diameter) 
may induce a greater immune response and be taken up by phagocytosis [157, 158].  
Varying both the solvent miscibility and the homogenization speed seems to be an 
effective way at varying particle size.  In some cases, it has been reported that increasing 
solvent miscibility results in an increase in particle size because of faster solvent 
withdrawal during the evaporation/solidification step [57].  However, particle formation 
takes place initially during the second emulsion step and this step seems to dominate the 
final particle size.   
When there is an interface between the organic an aqueous phase then the 
interfacial tension is related to the mechanical work needed to increase the surface by the 
following equation:  
dW
 dA (3.6) 
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Utilizing the W/O/W method, the volume of organic phase used to form the emulsion 
droplets is constant.  Thus, increasing or decreasing the contact surface area between the 
aqueous organic interface results in an inversely related increase or decrease in particle 
radius: 
SA
3V
 r (3.7) 
As a result, when there is an organic-aqueous interface, adding work to the system in the 
form of homogenization results in an increase in the surface area between the two phases 
and hence a decrease in particle radius. 
By this same rationale, if the amount of work put into the system is constant (i.e. 
same homogenization speed) and only the interfacial tension is changed (i.e. different 
ratios of DCM and acetone), then decreasing the interfacial tension results in an increase 
in the surface area of the organic-aqueous interface and thus, a decrease in droplet radius.  
This trend is shown in Figure 3.5 with the exception of an outlying data point at the 
solvent ratio of 20% DCM and 80% acetone.  It is believed that because of the high 
amount of acetone that the acetone extracts into the outer aqueous phase and as it does 
this, small particles begin to form as the PLGA precipitates out of the organic phase.  
Therefore, the DCM and PLGA that remains in the organic phase results in the formation 
of larger particles.  This disparity is not observed in the solvent ratios with lower 
percentages of acetone because it is not believed that enough acetone is present to enable 
particle formation through precipitation.  Rather, particle formation seems to result 
primarily from the formation of emulsion droplets. 
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Another way to relate the radius to the interfacial tension is through the Laplace 
pressure. When particle emulsion droplets are formed during the second homogenization 
step the emulsion droplet size is related to the organic-secondary aqueous phase 
interfacial tension and the droplet Laplace pressure according to equation 3.8 [63].  By 
correlating an increasing solvent miscibility with a decrease in interfacial tension 
between the organic-aqueous interface then as per equation 3.8, the decreased interfacial 
tension (increased solvent miscibility) can be linked to the decreased size [63]. 
)p(
2γ
r

 (3.8) 
r = particle radius 
γ = interfacial tension 
p(  ) = Laplace pressure 
It is also noticed that the size of particles made with an immiscible solvent, like 
DCM, are more affected by homogenization speed then the particles made with a 
miscible solvent, like acetone.  Therefore, increasing the homogenization speed and 
indirectly, increasing the Laplace pressure, is more effective at lowering particle size 
when there is a higher interfacial tension.  Also, for analysis of particles with a wide size 
disparity and Non-Gaussian distribution, sizing directly through SEM image analysis is 
an effective way at getting a true representation of particle size and dispersity. 
3.4.2 Lysozyme Loading 
While it was important to be able to make particles of varying sizes, it is equally 
important to demonstrate that the preparation conditions are still conducive to 
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incorporating active protein within the particles.  Traditionally, PLGA particles made 
with completely miscible solvents such as acetone are made by simply precipitating the 
polymer out of the solvent phase into an aqueous phase.  This type of method tends to 
result in poor protein loading [56].  However, by emulsifying the organic and aqueous 
phases prior to adding to the second aqueous phase, loading efficiencies are comparable 
to those of the more traditional solvents (DCM and ethyl acetate) used with the W/O/W 
double emulsion process.  The W/O/W double emulsion technique is typically used to 
incorporate hydrophilic proteins within a hydrophobic polymer and the emulsion supplies 
the energy necessary to overcome this thermodynamically undesirable process.  This is 
most noticeable with a partially miscible solvent like ethyl acetate where there is lower 
interfacial tension between the organic-aqueous interface and proteins can potentially 
leach out into the outer aqueous phase.  As a result, increasing homogenization speed 
seems to help maintain the protein within the organic phase and thus improve loading.  
With an immiscible solvent like DCM, once the protein is entrapped within the organic 
phase by the first emulsion, it is not as likely to leach out into the outer aqueous phase 
and thus, increasing homogenization speed does not have a significant contribution to 
improved loading.  However, when a miscible solvent like acetone is used, increasing 
homogenization speed results in decreased loading.  This is potentially because of how 
the particles are formed.   The first homogenization serves to emulsify the protein with 
the PLGA, but in the second emulsion, the particles are formed by precipitating polymer 
and not by emulsifying two immiscible phases.  Thus, the act of the polymer precipitating 
seems to entrap the protein and the additional homogenization serves only to dissociate 
the protein from the particles.  In general, increasing the PLGA concentration in the 
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organic phase increases loading efficiency, but lowers the protein weight percentage 
within the particle.  This is primarily because increasing the amount of PLGA both 
increases the amount of PLGA available to entrap the protein and decreases the 
theoretical amount that could be entrapped in a given amount of particles.  Increasing 
polymer concentration has also been found to improve loading efficiency because of a 
higher viscosity and a faster precipitation rate of the polymer within the organic phase 
[57, 78, 80, 159].  The higher viscosity can reduce drug diffusion out of the polymer 
droplets and the faster precipitation can help prevent protein diffusion across the organic-
aqueous phase boundary [79, 80].  However, while lower PLGA concentrations may not 
be as efficient, the lower PLGA amount results in higher weight percentages of protein 
within the particles. 
 The use of SAIB in the particles resulted in improved loading regardless of which 
solvent is used.  This was expected because the inclusion of SAIB is done to increase 
particle viscosity and limit protein diffusion out of the particles [108].  The inclusion of 
SAIB along with PLGA may also reduce the solubility within the organic phase.  Lower 
solubility has been shown to increase the polymer droplet solidification rate which in turn 
has been shown to improve loading [57, 78].  During particle synthesis, the first and 
second emulsion steps are important for both particle formation and protein 
incorporation.  Once the particles are formed they are subjected to the evaporation phase 
to allow for solvent removal.  At the evaporation phase the entrapped protein can diffuse 
out of the particles and into the outer aqueous phase.  Limiting protein diffusion into the 
outer aqueous phase by the incorporation of SAIB can help to increase protein loading. 
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3.5 Conclusions 
Modifications to the preparation procedure had significant impacts on particle 
size, size dispersity and protein loading.  Increasing solvent miscibility and hence 
lowering the interfacial tension between the aqueous-organic interface resulted primarily 
in decreases in particle size and size dispersity.  The use of the W/O/W double emulsion 
procedure enabled adequate protein loading regardless of the type of solvent used.  
Lowering the interfacial tension minimized the impact of homogenization forces on 
particle size and particle dispersity.  The particle size results representing the effects of 
homogenization forces and interfacial tension were consistent with thermodynamic 
principles relating the interfacial tension to work put into the system and to the contact 
area between the organic-aqueous interfaces.  Increasing the amount of PLGA in the 
organic phase resulted in gains in loading efficiency, but at the cost of lower particle 
protein weight percent.  The addition of SAIB in the organic phase resulted in improved 
protein loading.  While it is important to understand the effect of preparation conditions 
on particle size and loading, it is critical to evaluate the impact of preparation conditions 
on protein activity and assess the ability of particles to deliver active protein.   
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Table 3.1: DCM to Acetone Ratios 
Solvent Ratio (DCM:Acetone) 
wt:wt 
Volume (ml) 
DCM : Acetone 
100:0 - 
80:20 12.075 : 5.063 
60:40 9.057 : 10.127 
40:60 6.038 : 15.190 
20:80 3.019 : 20.253 
0:100 - 
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Figure3.1: SEM Images. (A) Solvent DCM, 25krpm homogenization, 3kx magnification, scale 
bar 3 m; (B) Solvent DCM, 10krpm homogenization, 1kx magnification, scale bar 10 m; (C) 
Solvent Ethyl Acetate, 25krpm homogenization, 6kx magnification, scale bar 2 m; (D) Solvent 
Ethyl Acetate, 10krpm homogenization, 4kx magnification, scale bar 3 m; (E) Solvent Acetone, 
25krpm homogenization, 10kx magnification, scale bar 1 m; (F) Solvent Acetone, 25krpm 
homogenization, 10kx magnification, scale bar 1 m. 
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Figure 3.2: Effect of particle preparation conditions on particle size and size deviation. Error bars 
indicate standard deviation, n=3. 
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Figure 3.3: Effect of solvents, homogenization speed (A) and PLGA concentration (B) on 
Polydispersity Index 
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Figure 3.4: Histograms illustrating particle size distribution. PLGA concentration 25mg/ml.  
Particle average diameter is listed as mean ± standard deviation (n=3). 
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Figure 3.5: Effect of Acetone:DCM solvent ratio on particle size and size deviation. PLGA 
concentration: 25 mg/ml.  Homogenization speed: 15 krpm.  Error bars indicate standard 
deviation, n=3. 
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Figure 3.6: SEM images of particles made with a variable ratio of acetone and DCM in the 
organic phase.  PLGA concentration: 25 mg/ml.  Homogenization speed: 15 krpm.  Magnification 
2kx. Scale bar 5 m.  
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60% DCM 40% DCM 
20% DCM 0% DCM 
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Figure 3.7: Effect of PLGA concentration on loading efficiency and protein weight % of particle.  
Homogenization speed 25krpm.  Error bars indicate standard deviation, n=3. 
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Figure 3.8: Effect of homogenization speed on loading efficiency and protein weight % of 
particle.  PLGA concentration 25mg/ml.  Error bars indicate standard deviation, n=3. 
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Table 3.2: Effect of Additive (SAIB) on Particle Loading 
Solvent Composition Loading Efficiency 
(%)* 
Weight %* 
DCM 
PLGA 72.32 ± 1.14 1.45 ± 0.02 
PLGA+SAIB 89.82 ± 0.61 1.80 ± 0.01 
Ethyl Acetate 
PLGA 58.75 ± 3.48 1.17 ± 0.07 
PLGA+SAIB 69.22 ± 3.46 1.38 ± 0.07 
Acetone 
PLGA 53.61 ± 1.07 1.07 ± 0.09 
PLGA+SAIB 70.68 ± 3.87 1.41 ± 0.08 
PLGA: 25mg/ml 
PLGA+SAIB: (20mg PLGA + 5mg SAIB)/ml 
* Values are listed as mean ± standard deviation (n=3). 
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4 Chapter 4:  Analysis of Preparation Conditions on Protein Activity and 
Sustained Release Properties 
4.1 Introduction 
The biggest disadvantage associated with protein loaded PLGA particles involves 
damage to protein during particle preparation.  This damage is primarily linked the 
organic-aqueous interface developed during the W/O/W double emulsion procedure.  
Any methods to lessen the damage caused to the proteins have significant clinical 
benefits because they increase the viability of particles use as a delivery device, 
especially with the high cost of many therapeutic proteins.  Therefore, while Chapter 3 
sought to evaluate preparation parameters and the impact on particle size, size dispersity 
and loading, Chapter 4 seeks to further this evaluation by assessing the impact of 
preparation parameters on protein activity and sustained release. 
Another disadvantage of incorporating proteins into polymer based particles using 
the W/O/W method involves a significant burst release within the first day or two.  While 
the burst release characteristics are analyzed, overcoming burst release and creating a 
more linear release profile is beyond the scope of this research.  This is because the 
motivating application that sparked a lot of this research actually requires a burst release 
from particles.  In other words, if therapeutic growth factors were to be delivered directly 
to spinal tissue, then the first injection would entail a higher bolus amount of growth 
factors and the subsequent injections would be lower levels meant to sustain the presence 
of the growth factors in the spinal tissue.   
Ultimately, the focus of this chapter is to analyze the effect of preparation 
conditions on protein stability and assess the impact on the sustained release of active 
protein.  Multiple preparation parameters such as solvent type, homogenization speed, 
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additives and freeze-drying methods are evaluated.  In addition, a novel, simplistic 
mathematical model was developed to characterize the multiple phases of protein release. 
4.2 Experimental Section 
4.2.1 Materials 
 Poly(lactide-co-glycolide) (PLGA, average molecular weight (MW) 18 kDa, 
copolymer ratio 50:50) (Figure 1) was purchased from Lakeshore Biomaterials 
(Birmingham, AL).  Lysozyme (MW 14.3 kDa, Activity 63,628 Units/mg protein), 
bovine serum albumin (BSA, MW 66 kDa), sucrose acetate isobutyrate (SAIB, MW 
846.91 Da), sodium azide (MW 65.01 Da) and Dulbecco’s Phosphate Buffered Saline 
(PBS, pH 7.4, KCl – 0.2 g/L, KH2PO4 – 0.2 g/L, NaCl – 8.0 g/L and Na2HPO4 – 1.15 
g/L) were purchased from Sigma-Aldrich (St. Louis, MO).  Poly(vinyl alcohol) (PVA, 
average MW 25 kDa, 88% hydrolyzed) was purchased from Polysciences, Inc. 
(Warrington, PA).  Lysozyme activity assay (Enzchek® assay) was purchased from 
Invitrogen (Carlsbad, CA) and lysozyme concentration assay (Pierce Micro BCA™ 
assay) was purchased from Thermo Scientific (Rockford, IL).  All organic solvents were 
of HPLC grade and purchased from Sigma-Aldrich (St. Louis, MO). 
4.2.2 Methods 
4.2.2.1 Particle Preparation 
Particles were prepared by a W/O/W double emulsion solvent evaporation 
procedure.  Phase volume ratios and surfactant (PVA) type and concentrations 
established by Dziubla et. al. were utilized [93].  The first water-oil phase contained 250 
l of an aqueous solution consisting of lysozyme (5 mg/ml) or lysozyme + BSA (5 + 100 
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mg/ml, respectively) in PBS plus 2.5 ml of an organic solution consisting of PLGA (10, 
20, 25 or 30 mg/ml) or PLGA + SAIB (20 + 5 mg/ml, respectively) in DCM, ethyl 
acetate or acetone.  The first water-oil phase was homogenized (Polytron® System 
PT3100 homogenizer with PT-DA 3007/2EC dispersing aggregate, Kinematic, Inc, 
Bohemia, NY) for 1 minute at speeds 10,000, 15,000, 20,000 or 25,000 rpm.  The first 
emulsion was then removed and slowly pipetted into 12.5 ml of 2 (w/v) % PVA kept at 
4˚C while being homogenized at the same speed as the first emulsion.  The second 
emulsion was homogenized for two minutes.  To allow for solvent removal, the second 
emulsion was then added to 25 ml of 2 (w/v) % PVA and allowed to stir overnight at 350 
rpm.   Particles were then collected by centrifuging at 15,000 G for 30 to 50 minutes.  
The particles obtained were washed twice in deionized (DI) water and centrifuged each 
time to collect.  After the final centrifuge, the particles were resuspended in 1 or 2 ml of 
DI water and flash froze in liquid nitrogen prior to freeze drying.  To avoid PLGA 
degradation during storage, freeze-dried samples were stored under desiccant at -20˚C 
until use. 
4.2.2.2 In vitro Lysozyme Release Studies 
Glass vials used for release studies were treated with Sigmacote®.  Dry particles 
(30 mg) were weighed directly in vials and resuspended in 2mls of release media (PBS 
(pH 7.4) + 0.1 % Sodium Azide).  Before sampling, particles were separated from the 
media by centrifuging and the supernatant was collected.  Centrifugation speeds and 
times were based on the minimum amount of centrifuging that still allowed for complete 
separation of the particles from the supernatant.  Centrifugation time was five minutes 
and the speeds varied from 8,000 G for particles made with DCM as the solvent to 12,000 
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G for particles made with acetone as the solvent.  All but 150 l of release media was 
removed per sample and an equal amount of release media was added prior to 
resuspension of the particle.  As the release experiments proceeded, the total release 
media volume was lowered to 1 ml to ensure that the concentration measurements were 
within the detectable range of the concentration assay (BCA™ assay).  Samples were 
performed in triplicate. Blank particles loaded without protein were also performed in 
triplicate.   The purposed of the blank particles was to account for any absorbance or 
fluorescence caused by degraded particles. The supernatant collected was assayed for 
protein concentration (BCA™ assay) and activity (EnzChek® assay).  The EnzChek® 
assay measures lysozyme activity on Micrococcus lysodeikticus cell walls, which are 
labeled with fluorescein such that the fluorescence is quenched.  Lysozyme action 
relieves this quenching resulting in an increase in fluorescence that is proportional to 
lysozyme activity.  The release media of  particles loaded with lysozyme and BSA was 
only assayed for activity (EnzChek® assay) because of the inability of the concentration 
assay (BCA™ assay) to distinguish between the two proteins. 
4.2.2.3 Effect of Preparation Conditions on Lysozyme Amount and Activity 
Remaining 
Protein solution was subjected to the particle preparation procedure.  The 
procedure is similar to the particle preparation procedure except for the absence of PLGA 
and the use of PBS instead of PVA during the final evaporation procedure.  The absence 
of PLGA allowed for a way to quantify the direct effects of the preparation procedure on 
lysozyme in terms of the soluble fraction remaining and the activity of the soluble 
fractions.  The use of PBS instead of PVA during the evaporation step was done to 
minimize interference caused by PVA on the concentration assay (BCA™ assay) and 
80 
 
because PLGA particles were not formed, the stabilizing properties of additional PVA 
were not critical.  The first water-oil phase contained 250 l of an aqueous solution 
consisting of lysozyme (5 mg/ml) in PBS plus 2.5 ml of an organic solvent (DCM, ethyl 
acetate or acetone).  The first water-oil phase was homogenized (Polytron® System 
PT3100 homogenizer with PT-DA 3007/2EC dispersing aggregate, Kinematic, Inc, 
Bohemia, NY) for 1 minute at speeds of 10,000, 17,500 and 25,000 rpm.  The first 
emulsion was then removed and slowly pipetted into 12.5 ml of 2 (w/v) % PVA kept at 
4˚C while being homogenized at the same speed as the first emulsion.  The second 
emulsion was homogenized for one minute.  The second emulsion was then added to 25 
ml of PBS and allowed to stir overnight at 350 rpm.   Samples were also included that 
only subjected the protein solution to the overnight evaporation step (no solvents or 
homogenizing) and that did not subject the protein to solvent, homogenizing or 
evaporation (control).  Samples were repeated in triplicate and assayed for protein 
concentration (BCA™ assay) and activity (EnzChek® assay).  Concentration 
measurements were done to determine the amount of soluble protein that remained in 
solution after being subjected to the preparation procedure.  Sample concentration and 
activity results were compared to the control to determine the percent remaining. 
4.2.2.4 Effect of Interfacial Tension on Lysozyme Amount and Activity Remaining 
 Lysozyme at a concentration of 5 mg/ml was subjected to the particle preparation 
conditions with a variable acetone and DCM ratio in the organic solvent.  Volume ratios 
of DCM and acetone utilized are listed in Table 3.1.  Because preliminary studies 
indicated that most if not all of the protein damage and denaturation occurred during the 
first emulsion step, only the first emulsion step was included for this study.  Briefly, the 
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lysozyme solution (250 l) was combined with the solvent/organic phase (2.5 ml) and 
homogenized at 25,000 rpm for 1 min.  The solvent phase did not contain PLGA.  This 
emulsion was then added to 12.5 ml of 2 (w/v)% PVA and 25 ml of PBS and stirred 
overnight at 350 rpm.  After the overnight evaporation, sample volume was recorded and 
sample concentration (BCA™ assay) and activity (EnzChek® assay) were measured.  
Samples were repeated in triplicate.  Concentration and activity values were compared to 
a control to determine the percent remaining.  The control consisted of 250 l of 5 mg/ml 
lysozyme in PBS that was added to 12.5 ml of 2 (w/v)% PVA and 25 ml of PBS.  The 
PBS and PVA mixture was stirred overnight prior to the addition of lysozyme.  This was 
done to maintain consistent volumes between the samples and the control. 
4.2.2.5 Addition of BSA and Effect on Lysozyme Activity 
Lysozyme with BSA as an additive was subjected to the W/O/W double emulsion 
solvent evaporation procedure.  The procedure is similar to the particle preparation 
procedure except for the absence of PLGA, the use of smaller volumes, the lower 
concentration of lysozyme in the first aqueous phase and the addition of the second 
emulsion to PBS instead of PVA.  The absence of PLGA allows for direct quantification 
of the effects of the preparation procedure on lysozyme activity.  Smaller volumes were 
used to maximize the shear forces generated in order to better differentiate the effects of 
homogenizing on protein activity.  A lower lysozyme amount was used to be more 
consistent with potential clinical protein amounts, to minimize any stabilizing effects that 
excess lysozyme may have and to be within the linear detection limits of the activity 
assay (EnzChek® assay).  The first water-oil phase consisted of 100 l of an aqueous 
solution with lysozyme (150 g/ml) and BSA at varying concentrations (0, 1, 5, 10, 20, 
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50, 100 and 150 mg/ml) in PBS plus 1 ml of DCM.  The first water-oil phase was 
homogenized for 1 minute at 25,000 rpm.   The first emulsion was then removed and 
pipetted into 5 ml of 2 (w/v) % PVA kept at 4˚C while being homogenized at 25,000 
rpm.  The second emulsion was homogenized for one minute and then added to 10 ml of 
PBS and allowed to stir overnight.  Samples were assayed for activity (EnzChek® assay) 
and the percentage of active protein remaining was determined by comparing samples to 
a control that was not subjected to homogenization, solvents or overnight stirring. 
4.2.2.6 Effect of Freeze-Drying on Lysozyme Activity and Release 
4.2.2.6.1 Effect on Activity 
 The effect of freeze-drying on lysozyme was determined by subjecting lysozyme 
solutions with varying concentrations of a stabilizing protein to freeze-drying after being 
frozen at different freezing rates.  Briefly, a lysozyme in water solution of 1.25 g/ml 
was used to prepare BSA solutions of 0, 1 and 5 mg/ml.  One ml of each solution was 
then frozen by either placing in a -20˚C freezer overnight (slow freeze) or by submerging 
in liquid nitrogen for 15 seconds (flash freeze).  Samples were then placed in a bench top 
lyophilizer for several days until completely dry.  Dried protein was then resuspended in 
1 ml of water.  Freeze-dried samples were compared to control samples that did not 
undergo freezing or freeze-drying.  Samples were repeated in triplicate and assayed for 
protein activity (EnzChek® assay). 
4.2.2.6.2 Effect on Release 
 PLGA particles were prepared by the same W/O/W method mentioned in Section 
4.2.2.1.  The primary aqueous phases consisted of 250 l lysozyme in PBS (5 mg/ml) or 
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just PBS.  The organic phase was 2.5 ml of PLGA in DCM at a concentration of 25 
mg/ml.  The secondary aqueous phase and evaporation phase consisted of 2 (w/v) % of 
PVA.  Homogenization speed was maintained at 25,000 rpm.  DCM was evaporated 
overnight and the samples were washed and collected by centrifugation. 
 After the final centrifugation step, samples were either freeze-dried (flash froze + 
lyophilization), flash-frozen only, or left alone.  The freeze-dried samples were 
resuspended in 2 ml of water, flash-frozen in liquid nitrogen, and then placed in a bench 
top freeze-dryer for several days until dry.  The frozen samples were flash-frozen in 
liquid nitrogen and stored in the freezer (-20°C) prior to use.  The non-frozen samples 
were refrigerated for less than one day until the start of the release study. 
 Preliminary samples were prepared to determine the amount of residual water in 
the pellet after the final centrifugation step. 
 In vitro lysozyme release studies were performed according to the procedure 
mentioned in section 4.2.2.2 with the following exceptions.  The entire batch of non-
frozen, frozen and freeze-dried particles were utilized for the release study and 
resuspended in PBS (37°C) at a final particle concentration of 15 mg/ml.  Release 
samples were taken and analyzed according to procedures in section 4.2.2.2.  Samples 
were repeated in triplicate. 
4.2.2.7 Statistical Analysis 
 The results are presented as mean ± standard deviation.  Significant trends in 
group data were determined using two factor analysis of variance (ANOVA).  
Significance between two data points was determined using single factor ANOVA.  
Statistical significance was considered at p < 0.05. 
84 
 
4.3 Results 
4.3.1 Effect of Preparation Conditions on Lysozyme Amount and Activity 
Remaining 
Subjecting lysozyme to the particle preparation conditions allowed for direct 
quantification of the effects of the preparation procedure on protein in terms of the 
soluble fraction that remained and the activity of that soluble fraction.  Three different 
solvents were evaluated, DCM, ethyl acetate and acetone as well as three different 
homogenization speeds, 10 krpm, 17.5 krpm and 25 krpm (Figure 4.1).  The effect of 
overnight stirring (evaporation phase) on protein was also determined.  The results 
indicated that DCM was the harshest of the three solvents with respect to the amount and 
activity of protein remaining.  DCM as a solvent resulted in the least amount of soluble 
protein and active protein remaining.  The amount of soluble protein was greater than the 
amount of active protein.  Increasing homogenization speed resulted in an increase loss 
for both the amount and activity of protein when DCM was the solvent (p < 0.05).  
Solutions with ethyl acetate and acetone as solvents demonstrated more soluble and 
active protein remaining as compared to solutions with DCM as the solvent.  When the 
solvents ethyl acetate and acetone were used, the amount of protein remaining was 
similar to the activity of protein remaining.  This indicates that most of the protein 
detected through a concentration assay was active.  Increasing homogenization speed for 
ethyl acetate and acetone as solvents did not have a significant effect (p > 0.05) on the 
protein amount or activity remaining.  The use of the evaporation phase did not cause a 
detectable loss in the protein amount and caused a minor loss in protein activity. 
The interfacial tension values between the solvent phase and the aqueous phase 
were changed by varying the ratios of DCM and acetone in the solvent phase.  DCM is an 
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immiscible solvent (1.6 % solubility in water) with a relatively high organic-water 
interfacial tension value of 28.3 mN/m.  On the other hand, acetone is a completely 
miscible solvent in water which means there is no interface between the acetone and 
water resulting in negligible interfacial tension values.  Therefore, increasing the amount 
of acetone in the solvent phase increases the solvent miscibility in water and lowers the 
aqueous-organic interfacial tension.  The impact on the amount and activity of lysozyme 
remaining in solution when subjecting lysozyme to emulsion conditions with varying 
ratios of DCM and acetone in the organic phase is illustrated in Figure 4.2.  In nearly all 
cases the amount of lysozyme remaining in solution is consistent with the activity of 
lysozyme remaining, indicating that the lysozyme remaining in solution is active.  The 
lowest percentage remaining of protein in solution and active protein occurs at 100% 
DCM.  The highest amount of lysozyme remains in solution at 100% acetone and the 
highest amount of active lysozyme remains at 40% DCM.  Overall, the trend indicates 
that decreasing the ratio of DCM to acetone increases both the amount of soluble and the 
amount of active protein remaining in solution. 
4.3.2 Lysozyme Release 
Particles consisting of PLGA and PLGA + SAIB were prepared in three different 
solvents, DCM, ethyl acetate and acetone.  Particles were resuspended in PBS and media 
samples were taken by centrifuging the particles and assaying the supernatant for both the 
protein concentration and activity.  All samples showed a burst release indicating that 
SAIB is not as effective at preventing a burst release in smaller (< 1 m) size particles as 
compared to micron size particles [108].  These results are represented in Figure 4.3.  All 
samples demonstrated a sustained release of active protein for over 60 days.  Although all 
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samples tested demonstrated a high initial burst release, there were still significant 
differences between the total percent release of active protein when different solvents 
were used.  The percent release of active protein was the highest when acetone was the 
solvent and the lowest when DCM was the solvent.  The percent and total amount of 
active protein released increased with increasing solvent miscibility.  The cumulative 
percentages and amounts of active protein released are listed in Table 4.1.  When DCM 
and ethyl acetate were the solvents to make PLGA particles a degradation release resulted 
after 35 days however, the increase in protein activity did not follow the same increase 
indicating that all the protein released was not active.  The addition of SAIB in the DCM 
and ethyl acetate samples seemed to reduce this degradation release.  Except for the cases 
of the degradation release, the concentration of protein coincided with the activity of the 
protein. 
4.3.3 Release Model 
Release from particles made with DCM as the solvent were utilized for generating 
the release model.  Release was modeled as a tri-phasic release pattern where the first two 
days was modeled as desorption release of surface associated proteins, days two to 
twenty three were modeled as fickian diffusion release from the particle matrix, and for 
the remaining time, release was modeled as fickian diffusion release with the exception 
that the diffusion coefficient increased as the polymer matrix degraded.  Therefore, the 
following equations were utilized for each phase: 
Phase I: Desorption (burst release) – days 0 to 2 
tk- de  
m(0)
m(t)
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kd = desorption rate constant (s
-1
) = 0.0001 s
-1
 
Phase II:  Fickian diffusion (constant DAB) – days 2 to 23 
222
 AB t/RnD-
1n
22
Ao
A e
n
16
  
m
(t)m
 
R = Particle radius = 0.000025 cm 
DAB = Coefficient of diffusion of protein in particle (cm
2
/s) = 1.5359 x 10
-18
 (cm
2
/s) 
Phase III: Fickian diffusion (DAB = f(degradation)) – days 23 to 63 
222
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22
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n
16
  
m
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 t)(k e  a  (t)D degr - DAB  
a = constant = 1.0 x 10
-19
 
kD-degr = degradation rate constant of diffusion (s
-1
) = 1.35 x 10
-6
 s
-1
 
The degradation rate constant of diffusion represents a scaling factor relating particle 
degradation to the diffusion coefficient.  In Figure 4.4a, during the degradation phase, a 
best fit analysis was done to determine values of DAB. In Figure 4.4a, values of DAB 
during the degradation phase are plotted on a logarithmic scale as a function of time.  In 
Figure 4.4b, the equation for DAB as a function of time is plugged into the release 
equation for the degradation phase. 
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4.3.4 Addition of BSA and Effect on Lysozyme Activity 
Increasing the amount of BSA in the primary water phase containing lysozyme 
and subjecting the protein solution to the particle preparation procedure resulted in an 
increase in the percent of lysozyme activity remaining as seen in Figure 4.5 (p < 0.01).  
The maximum percentage of activity remaining was reached at a BSA concentration of 
100 mg/ml with a percentage activity remaining of 79.5 ± 0.2% versus 8.6 ± 4.2% for 
lysozyme homogenized at 25 krpm with no BSA.  At a BSA concentration greater than 
100 mg/ml, 150 mg/ml, the activity remaining no longer increased, potentially from 
interference caused by an excessive amount of BSA that may inhibit the ability of 
lysozyme to interact with the Micrococcus lysodeikticus cell walls featured in the 
EnzChek® assay.   
BSA as an additive was also effective at increasing the total amount of active 
protein delivered for samples made with the solvents: DCM, ethyl acetate and acetone 
(Figure 4.6).  The total cumulative amounts of active protein released are listed in Table 
4.2.  When the solvents were DCM and ethyl acetate, BSA seemed to shorten the time it 
took for the secondary (degradation) release to take place (20 days vs. 35 days), and 
increase the amount of active protein delivered during the degradation release.  For all 
solvents used, the addition of BSA caused the particles to degrade faster and hence 
resulted in the release study being stopped at day 50 as opposed to day 62 for the 
particles without BSA.  The increased particle degradation is potentially caused by 
increased protein within the particles which may result in increased water uptake. 
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4.3.5 Effect of Freeze-Drying on Lysozyme Activity and Release 
Lysozyme in solution was frozen two different ways, slow-freeze and flash 
freeze, and exposed to freeze-drying to evaluate impact of freeze-drying on lysozyme 
activity.  Stabilizing ability of BSA at two different concentrations (1 and 5 mg/ml) was 
also evaluated.  Results are indicated in Figure 4.7.  Without the inclusion of BSA as a 
stabilizer, freeze-drying had a negative impact on lysozyme activity regardless of how the 
samples were frozen.  Freezing the lysozyme solution overnight in the freezer was 
slightly more detrimental to the protein activity then flash-freezing the lysozyme solution 
in liquid N2.  When BSA was included in the lysozyme solution, there was no significant 
loss in lysozyme activity regardless of how the freeze-dried samples were frozen.   
Release profiles of PLGA particles subjected to freezing and freeze-drying are 
shown in Figure 4.8.  Particles that were freeze-dried showed a slightly higher burst 
release when compared to the particles that were frozen only and particles that were not 
frozen.  The amount of initial lysozyme released from non-frozen, frozen and freeze-
dried particles was 2704.1 ± 222.1 g, 2612.6 ± 133.9 g and 3281.0 ± 556.5 g, 
respectively.  The activity of lysozyme initially released from non-frozen, frozen and 
freeze-dried particles was 12340.3 ± 2566.6 units, 13486.0 ± 1001.1 units and 17193.4 ± 
2467.6 units, respectively.  However, in both cases of amount released and active amount 
released, the additional release from the freeze-dried particles is statistically insignificant 
when compared to the non-frozen particles.  Other than a slightly higher insignificant 
initial burst release from the freeze-dried particles, the release profiles were similar. 
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4.4 Discussion 
4.4.1 Effect of Preparation Conditions on Lysozyme Amount and Activity 
Remaining 
Ultimately, the ability to incorporate active proteins within particles is critical for 
the function of particles as a protein delivery system.  Proteins subjected to preparation 
conditions with DCM as a solvent underwent increased denaturation and thus had greater 
levels of loss in the amount and activity remaining.  Decreases in the amount of protein 
remaining are an indication of protein misfolding and agglomeration.  This could cause 
insoluble aggregates that precipitate out of solution and become undetectable to the 
concentration assay.  The higher levels in protein loss when DCM is used as a solvent are 
explained because hydrophobic solvents like DCM generate a large hydrophobic surface 
area at the aqueous-organic interface. Increased homogenization results in an increase of 
this hydrophobic surface area and thus an increase in the damage done to proteins [93].  
For partially miscible and totally miscible solvents like ethyl acetate and acetone, 
respectively, there is a less distinct aqueous-organic interface and hence less protein 
damage.  Plus, because the total surface area of this interface is not as effected by 
homogenization speed as it is with DCM as the solvent, the effect of homogenization 
speed on protein activity loss is insignificant. 
Figure 4.2 illustrates the impact of keeping homogenization (energy input) the 
same while only changing the solvent miscibility.  Increasing the solvent miscibility by 
increasing the amount of acetone in the solvent phase is believed to decrease the 
interfacial tension between the organic and aqueous phases. Thus it is seen that 
decreasing interfacial tension results in less protein damage.  This is the result of a less 
distinct aqueous-organic interface.  Plus, because the addition of acetone increases the 
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miscibility of the solvent phase, some of the solvent phase is dissolving into the aqueous 
phase and thus lowering the total volume in the solvent phase.  According to equation 4.1 
the volume of solvent in the organic phase is directly related to the droplet radius and the 
surface area between the organic-aqueous phase.  By reducing the total volume in the 
solvent, the result is a decrease in the droplet radius, and a potential decrease in the 
contact surface area between the two phases.  Because protein damage is believed to 
occur primarily at the organic-aqueous interface, then decreasing the contact area of this 
interface should reduce protein damage. 
(r)(SA)  3V  (eq. 4.1) 
V = total volume of organic phase (ml) 
r = droplet radius 
SA = total surface area of the organic-aqueous interface 
 In Figure 4.2, reducing the ratio of DCM in the organic phase shows similar 
values for both the amount remaining and activity remaining of lysoyzme.  This indicates 
that if the lysozyme remains in solution and does not precipitate out because of 
misfolding, the lysozyme is active.  The trend of decreasing the amount of DCM and 
decreasing the damaging effect on protein is consistent until the ratios of 20% and 0% 
DCM.  This is because at these solvent ratios, the protein is seen precipitating out when 
added to the solvent phase.  Therefore, when the emulsion is added back to the outer 
aqueous phase, the lysozyme must redissolve back into the outer aqueous phase to remain 
in solution.  This phenomenon is independent of the impact of interfacial tension on 
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protein and does not detract from the findings that decreasing interfacial tension 
decreases protein damage. 
4.4.2 Lysozyme Release 
 For nanoparticles to be clinically viable for sustained active protein delivery, it is 
important to assess the percentage of protein both active and inactive delivered with the 
varying solvents.  Increasing the solvent miscibility and hence, lowering the interfacial 
tension at the aqueous-organic interface, improves both the percentage of active protein 
released as well as the total amount of active protein released.  This is further indication 
that a lot of protein denaturation and misfolding takes place at this interface.  The 
advantages of increasing the total amount of active protein released by lowering the 
aqueous-organic interfacial tension are still relevant despite the high burst release seen in 
all samples.  Also, for particles made in DCM and ethyl acetate the degradation release 
seen after day 30 is confirmed by the concentration assay, but not by the activity assay 
indicating that the additional protein released is not active.  This is indication of the 
damaging microenvironment within the particles caused by the acidic degradation 
byproducts of PLGA.  SAIB was initially used to limit the burst release in micron size 
(24-30 m) size particles by increasing the viscosity within the particles and limiting the 
immediate diffusion of protein into the release media [108].  However, the average size 
of particles used for this study was on the submicron size scale.  The addition of SAIB 
does not have the same effect at reducing the burst release in submicron size particles as 
it does for micron size particles.  This is because the burst release is primarily caused by 
the immediate release of surface associated proteins and because the ratio of surface 
proteins to entrapped proteins is much higher for submicron than for micron size 
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particles.  When solvents DCM and ethyl acetate were used to make particles, a 
secondary (degradation) release was seen after day 30, however, when SAIB was used as 
an additive this degradation release was reduced.  The use of SAIB in PLGA particles has 
been shown to slow polymer degradation [108] and this seems to be the reason for the 
limited degradation release.  It is believed that the increased viscosity of PLGA particles 
with SAIB limits water uptake and thus slows PLGA degradation. 
4.4.3 Release Model  
Because protein released from particles is the result of three distinct phases, it is 
useful to model the release as such.  While there have been various attempts to model 
protein release from particles most models are limited because they try to identify the 
release with one continuous model [139, 160-163].  In this case a tri-phasic model 
simplifies the modeling requirements and is a better representation of the mechanisms 
causing protein release.  This type of model also allows for the creation of a scaling 
parameter that relates the diffusion coefficient to the particle degradation. 
It is worth mentioning that during the diffusion release period of the model, days 
2 to 23, that diffusion based released is extremely slow as seen by a diffusion coefficient 
of only 1.5359 x 10
-18
 cm
2
/s.  Diffusion coefficients for small molecules diffusing 
through glassy polymers are on the order of 10
-10
 to 10
-16
 cm
2
/s [164].  Therefore, such a 
low diffusion coefficient on the order of 10
-18
 cm
2
/s is potentially representative of a large 
macromolecule like lysozyme diffusing through a glassy polymer.  The Tg of PLGA is 
approximately 40°C and because the release studies were carried out at 37°C, then the 
PLGA polymer matrix within the particles was in the glassy phase.  However, such a low 
diffusion coefficient raises the possibility that alternative mechanisms were involved 
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other than simple fickian diffusion.  For example, although PLGA was in the glassy 
phase, the coefficient for water diffusing into a glassy PLGA polymer is on the order of 
10
-8
 cm
2
/s indicating that water molecules will penetrate the particle core within minutes 
after the start of the release study [139].  This leaves open the possibility that the PLGA 
polymer matrix is not completely static and that pore formation may result as PLGA 
monomers and oligomers are removed by the infusing water.  Thus, protein diffusion 
through the polymer matrix may be reliant on the formation of pores within the network 
and the creation of cracks that provide a pathway for protein release.  Therefore, although 
protein release during days 2 to 23 fits a fickian release model extremely well, the low 
order of magnitude of the diffusion coefficient raises the possibility that fickian diffusion 
is not the only mechanism responsible for protein release and that the slow release is the 
result of kinetic changes within the glassy polymer that give rise to alternative release 
pathways. 
4.4.4 Addition of BSA and Effect on Lysozyme Activity 
 BSA has been used as an additive because of its ability to occupy the aqueous-
organic interface and act as a stabilizer [74, 109].  As indicated in Figure 4.1, DCM is 
more damaging to lysozyme than ethyl acetate or acetone, potentially because of the 
hydrophobicity of the aqueous-organic interface.  Therefore, DCM was used as the 
solvent of interest to test the effect of BSA concentration in the primary aqueous phase 
and the ability to stabilize the protein of interest, lysozyme.  Increasing the amount of 
BSA resulted in an increase in the percentage of active protein remaining until it is 
believed the amount of BSA began to interfere with the ability of lysozyme to 
enzymatically break down the bacterial cell wall.   
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 Evaluation of BSA as an additive on the total amount of active protein released 
demonstrated the benefits of BSA on maintaining protein activity.  Despite increases 
primarily in the initial burst release, the addition of BSA leads to an increase in the 
amount of active protein released regardless of the type of solvent used.  In addition to 
the damaging effects of particle preparation on protein stability, another potential cause 
for protein damage is the acidic microenvironment of degrading PLGA particles [86].  By 
incorporating BSA in the particles along with lysozyme, BSA can both act as a proton 
scavenger and competitively bind to the PLGA in an effort limit incomplete protein 
release [86].   
4.4.5 Effect of Freeze-Drying on Lysozyme Activity and Release 
Because the effects of freezing and freeze-drying have shown to induce protein 
denaturation, the benefits of quick freezing and adding a stabilizer were evaluated.  
Because the act of freezing is potentially harmful to protein in solution, it is desired to  
reduce the freezing time [111].  This is done by flash-freezing the lysozyme solution in 
liquid in N2 as opposed to freezing the lysozyme solution overnight in a -20°C freezer.  
While flash-freezing shows slightly less damage to protein activity then overnight 
freezing, both methods indicate significant damage to the lyophilized lysozyme solution.  
In order to prevent this, a stabilizing protein, BSA, was added to the lysozyme solution.  
Solutions of at least 1 mg/ml of a stabilizing protein are recommended by the protein 
manufacturer (Pierce), plus these concentrations are consistent with protein 
concentrations commonly found in the body.  Ultimately, the addition of BSA as a 
stabilizing protein helped eliminate any harmful effects to lysozyme activity caused by 
freeze-drying. 
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The initial purpose for including BSA as a stabilizer was to reduce any damage 
caused to the protein that would be entrapped within the particles.  Since the particles are 
freeze-dried for storage the effect of freeze-drying on the entrapped protein was a 
concern.  However, it has been shown that incorporating protein within particles protects 
the protein from denaturation caused by freeze-drying [67, 69, 86, 89, 113].  Therefore, 
previous studies indicated that the addition of a stabilizing protein to protect the 
therapeutic protein from damage caused by lyophilization should not be necessary.  
However, there still remained the concern as to how freezing and lyophilization would 
affect protein release.  The concern was because a lot of the protein associated with the 
particles may not be entrapped within the particle, but rather, associated with the particle 
surface.  Plus, because the particles dry during freeze-drying through the sublimation of 
ice crystals, there was a concern that the escaping water vapor would create pores in the 
particles and potentially increase the particle surface area.  This increase in surface area 
may lead to the increase in the burst release of surface associated proteins.  Studies 
indicated only a slight increase in the initial release of lysozyme for the freeze-dried 
samples (Figure 4.9).  This indicates that any pores created during the freeze-drying 
process have little contribution to the increased surface area and the increased release of 
surface associated proteins.  Plus, freeze-drying shows no significant negative impact on 
active protein released. 
4.5 Conclusions 
Both Chapters 3 and 4 showed that modifications to the preparation procedure had 
significant impacts on particle size, protein loading, protein activity and protein release.  
Increasing solvent miscibility and hence lowering the interfacial tension between the 
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aqueous-organic interface resulted in decreases in particle size, dispersity and protein 
activity loss.  Lowering the interfacial tension minimized the impact of homogenization 
forces on particle size, particle dispersity and protein activity.  All particles tested 
provided sustained release of at least 50 days, while most provided sustained release over 
60 days.  Decreasing the aqueous-organic interfacial tension resulted in increases in both 
the percent and cumulative amount of active protein released.  When DCM was used as 
the solvent, the inclusion of BSA in the primary aqueous phase was most effective as a 
stabilizer at a concentration of 100 mg/ml.  At this concentration, the incorporation of 
BSA into the particles resulted in increases in the total amount of active protein delivered 
despite shortened release duration (50 vs. 62 days) because of the increased particle 
degradation.  The release profile represented tri-phasic release characteristics and a model 
was developed to represent this.  A scaling factor relating particle degradation to the 
diffusion coefficient was developed for the degradation release phase.  Finally, loading 
particles with protein proved adequate to stabilize lysozyme through the freeze-drying 
process and freeze-drying demonstrated a slight increase in the initial burst release of 
protein, but the increase was statistically insignificant. 
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Figure 4.1: Effect of preparation conditions on lysozyme amount remaining and activity 
remaining.  Error bars indicate standard deviation, n=3. 
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Figure 4.2: Effect of DCM:Acetone solvent ratio on protein activity and solubility.  Error bars 
indicate standard deviation, n=3. 
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Figure 4.3: Particle release data.  Error bars indicate standard deviation, n=3. 
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Table 4.1: Active Protein Released 
Solvent 
Particle Size 
(nm)* 
Cumulative % Active 
Protein Released* 
Cumulative Amount 
Active Protein Released 
(Units)* 
DCM 535.1±124.2 30.02±1.33%, 8288.3±367.2 
Ethyl Acetate 260.5±41.8 42.14±1.45% 9451.8±325.7 
Acetone 115.6±6.4 72.73±4.35%, 14886.5±890.7 
* Values are listed as mean ± standard deviation (n=3). 
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Figure 4.4: (A) Change in diffusion coefficient as a function of time at days 23 - 63. (B) Release 
model.  
(A) 
(B) 
 t)10 x (1.35 e  10 x 1.0  (t)D -6-19AB
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Figure 4.5: Addition of BSA and effect on lysozyme activity for W/O/W procedure.  Error bars 
indicate standard deviation, n=3. 
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Figure 4.6: Addition of BSA and effect on the cumulative release of active protein.  Error bars 
indicate standard deviation, n=3.  
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Table 4.2: Effect of BSA as a Stabilizer on Total Active Protein Released 
Solvent 
Total Active Amount 
Released Without BSA 
(Units)* 
Total Active Amount Released 
With BSA (Units)* 
DCM 8288.3±367.2 13880.6±420.3 
Ethyl Acetate 9451.8±325.7 13617.2±365.0 
Acetone 14886.5±890.7 18227.4±690.2 
* Values are listed as mean ± standard deviation (n=3). 
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Figure 4.7: Effect of freeze-drying on lysozyme activity.  Stabilizing impact of BSA.  Error bars 
indicate standard deviation, n=3. (*) p < 0.05. 
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Figure 4.8: Effect of freezing and freeze-drying on protein release.  Error bars indicate standard 
deviation, n=3. 
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5. Chapter 5:  Non-Thermal Atmospheric-Pressure Plasma Decontamination of 
Protein Loaded Biodegradable Nanoparticles 
5.1 Introduction 
It is desirable to develop protein loaded PLGA nano- sized particles that can be 
directly micro-injected into CNS tissue. Chapters 5 and 6 are meant to address the 
immune response noticed during preliminary in vivo studies.  This chapter describes the 
development of a novel particle sterilization method.  Because of the difficulty in 
preparing particles using the W/O/W double emulsion procedure under completely sterile 
conditions a novel method of inactivating bacteria present on protein loaded particles 
post-preparation was developed that could maintain particle integrity and protein activity.  
Particle sterilization is required to eliminate a potential negative immune response to 
contaminated particles.  The bacterial inactivation method developed in this work 
involves the resuspension of protein loaded particles in deionized (DI) water or PBS that 
has been subjected to a non-thermal atmospheric pressure discharge.   
 Current and more traditional sterilization methods involve exposure to ethylene 
oxide, chlorine, ozone, gamma radiation or heat [119, 120].  When certain polymers are 
sterilized utilizing these methods the results are unfavorable changes in physical, 
chemical and mechanical properties [120].  One of the most promising sterilization 
methods for the surface treatment of polymers is non-thermal (< 50˚C) atmospheric 
pressure plasma [120]. While the mechanism of non-thermal plasma sterilization is not 
entirely known, it has been shown safe enough for application directly to human tissue 
[119, 121].  Plasma discharge generates reactive oxygen species such as ozone (O3), 
peroxides, OH radicals, etc. that can react with and destroy bacteria [119, 121, 122].  
Since the reactive species generated can react with organic materials such as protein, 
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there has been evidence of plasma treatment causing significant protein activity loss 
[123].  Therefore, a plasma treatment method was developed so that the protein loaded 
particles would not have to come in to direct contact with the plasma discharge.  The 
specific type of plasma sterilization used in this work utilizes an electrode to discharge 
non-thermal plasma through water or PBS contained in a grounded well.  This treated 
water or PBS is then used as the sterilizing agent.  While indirect exposure to plasma is 
preferred to reduce damage to the particles and the protein, it is also less effective as a 
sterilizing agent [124]. This decontamination method has never been attempted with 
either PLGA particles or protein loaded PLGA particles so the sterilization effectiveness 
and effects on both the particles and the protein are unknown.  Because the particles can 
be prepared in a controlled laboratory setting bacterial inactivation is considered adequate 
when complete inactivation is achieved after exposure to a low bacterial load of E. coli at 
a concentration of 10
3
 CFU/ml.  For assessing the impact of indirect plasma sterilization 
on protein activity, the model protein lysozyme was used. 
5.2 Experimental Section 
5.2.1 Materials 
 Poly(lactide-co-glycolide) (PLGA, average molecular weight (MW) 18 kDa, 
copolymer ratio 50:50) was purchased from Lakeshore Biomaterials.  Lysozyme (MW 
14.3 kDa, Activity 63,628 Units/mg protein), bovine serum albumin (BSA, MW 66 kDa), 
sodium azide (MW 65.01 Da) and Dulbecco’s Phosphate Buffered Saline (PBS, pH 7.4, 
KCl – 0.2 g/L, KH2PO4 – 0.2 g/L, NaCl – 8.0 g/L and Na2HPO4 – 1.15 g/L) were 
purchased from Sigma-Aldrich.  Poly(vinyl alcohol) (PVA, average MW 25 kDa, 88% 
hydrolyzed) was purchased from Polysciences, Inc.  Lysozyme activity assay (Enzchek® 
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assay) was purchased from Invitrogen and protein concentration assay (Pierce Micro 
BCA™ assay) was purchased from Thermo Scientific.  All organic solvents were of 
HPLC grade and purchased from Sigma-Aldrich.  Escherichia coli (E. coli) were 
purchased from ATCC (#25922).  LB Broth, Miller (Luria-Bertani) and Brain Heart 
Infusion Agar were purchased from Becton, Dickinson and Company. 
5.2.2 Methods 
5.2.2.1 DBD Experimental Setup 
 Non-thermal atmospheric-pressure plasma was produced by a dielectric barrier 
discharge (DBD) following procedures previously described by Fridman et al [165].  
Plasma was generated utilizing a power supply with continuous waveform characteristics 
and a 2.54 cm diameter high-voltage electrode made of copper and covered with a 
dielectric barrier made from fused quartz (Fig. 5.1).  Two ml of deionized (DI) water or 
PBS was placed directly below the electrode in a grounded well that contained a 2 ml 
reservoir.  The electrode was kept approximately 1.5 mm above the top surface of DI 
water or PBS.  Plasma was discharged across the water or PBS and onto the grounded 
well at a power of 3.2 W and a surface power density of 0.63 W/cm
2
.  The 2 ml well sat 
on a grounded steel base.  Once the water or PBS was subjected to the plasma discharge 
at various time intervals, it was used to either resuspend particles or dilute lysozyme 
samples.  These studies are further explained below. 
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5.2.2.2 Escherichia coli 
E. coli was grown in 10ml of Miller’s LB broth at a slow shaking speed of 37˚C 
overnight.  The culture was then centrifuged and resuspended in sterile PBS.  The culture 
was then serially diluted to a concentration of 10
3
 CFU/ml for use in inactivation studies. 
5.2.2.3 Particle Preparation 
Particles were prepared by the W/O/W double emulsion solvent evaporation 
procedure.  Phase volume ratios and surfactant (PVA) type and concentrations 
established by Dziubla et. al. were utilized [93].  The first water-oil phase contained 250 
l of an aqueous solution consisting of lysozyme (5 mg/ml) or BSA (100 mg/ml) in PBS 
plus 2.5 ml of a DCM solution consisting of PLGA (25 mg/ml). Particles were loaded 
with lysozyme for loading and release studies to assess the effect of plasma treatment on 
loading and active protein release.  Particles were loaded with BSA to assess how BSA 
interferes with sterilization.  Because of the damaging effects of the w/o/w double 
emulsion procedure on protein, BSA has been utilized as a stabilizer [74, 109].  Earlier 
work showed that BSA had the maximum stabilizing effectiveness at a concentration of 
100 mg/ml [166].  The first water-oil phase was homogenized (Polytron® System 
PT3100 homogenizer with PT-DA 3007/2EC dispersing aggregate, Kinematic, Inc, 
Bohemia, NY) for 1 minute at 25,000 rpm.  The first emulsion was then removed and 
slowly pipetted into 12.5 ml of 2 % PVA kept at 4˚C while being homogenized at 25,000 
rpm.  The second emulsion was homogenized for two minutes.  To allow for solvent 
removal, the second emulsion was then added to 25 ml of 2 % PVA and allowed to stir 
overnight at 350 rpm.   Particles were then collected by centrifuging at 15,000 G for 20 
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minutes.  Particles were washed by resuspending in DI water and centrifuging each time 
to collect.  Particles were collected at various centrifugation steps for further testing.   
5.2.2.4 Scanning Electron Microscopy 
 To assess the effect of plasma treatment on particle morphology, after one wash 
particles were resuspended in 2 ml of DI water that had been plasma treated for 30s or 
60s.  Particles were washed several times after plasma treatment and collected by 
centrifugation. After the final centrifuge, particles were resuspended in 2 ml of DI water.  
A small sample of suspended particles was removed and diluted in water to an 
approximate concentration of 1 mg/ml.  40 l of this diluted sample was then pipetted 
onto an SEM stub and flash froze in liquid nitrogen.  The sample was then freeze-dried 
and sputter coated with a platinum/palladium mixture prior to imaging.  Size of the dried 
non-treated samples was determined directly using scanning electron microscopy (SEM) 
(Zeiss Supra 50VP) and Image J software.  Samples were prepared in triplicate and 200 
particles were counted per sample.   
5.2.2.5 Lysozyme Loading 
Lysozyme loading was determined for particles that underwent one wash step 
prior to being resuspended in plasma treated water that had been treated for 0s, 30s and 
60s.  Glass vials used for loading studies were treated with Sigmacote® (Sigma Aldrich, 
St. Louis, MO).  Sigmacote® is a thin layer of silicone deposited on the glass wall to 
prevent lysozyme adsorption on the glass wall.  After plasma treatment particles were 
washed twice and freeze-dried.  Dry particles were resuspended in 0.5 M NaOH (10 
mg/ml) and allowed to stir overnight until totally degraded.  The solution was then 
neutralized with an equal volume of 0.5 M HCl.  Samples were prepared in triplicate. 
113 
 
Blank particles without protein were also prepared and subjected to the same degradation 
and assay conditions to account for any absorbance caused by the degraded polymer.  
Standards were subjected to the same treatment and protein concentration was 
determined using the BCA™ assay.  The BCA™ is a color change assay the relies on the 
reduction of Cu
2+
 to Cu
1+
 in an alkaline medium followed by the highly selective and 
sensitive colorimetric detection of the cuprous cation (Cu
1+
) by bicinchoninic acid 
(BCA).  Encapsulation efficiency was calculated in terms of loading efficiency (eq. 5.1) 
and the protein weight percent of the particles (eq. 5.2).  
Particlesin  Lysozyme of Mass lTheoretica Total
Particlesin  Lysozyme of Mass
 x 100  (%)Efficiencyion Encapsulat   
(eq. 5.1) 
Lysozyme  Particles of Mass
Particlesin  Lysozyme of Mass
 x 100  %Weight  (eq. 5.2) 
5.2.2.6 BSA Loading 
 Because BSA is not completely soluble in a basic NaOH solution, BSA loading 
could not be determined directly.  Instead, loading was determined indirectly by 
measuring the amount of BSA in the supernatant after each particle centrifugation and 
wash step.  Therefore, the weight % of BSA in particles is determined according to 
equation 5.2 (substitute BSA for lysozyme), but the mass of BSA in particles is 
determined indirectly according to equation 5.3. 
Mass of BSA in Particles = Mass of BSA Loaded – Cumulative Mass of BSA in 
Supernatant  (eq. 5.3) 
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5.2.2.7 In vitro Lysozyme Release Studies 
Lysozyme release was performed on particles that underwent one wash step prior 
to being resuspended in plasma treated water that had been treated for 0s, 30s and 60s.  
After plasma treatment, particles were washed twice and freeze-dried.  Glass vials used 
for release studies were treated with Sigmacote®.  Dry particles (30 mg) were weighed 
directly in vials and resuspended in 2ml of release media (PBS (pH 7.4) + 0.01 % 
Sodium Azide).  Study was performed in a heated shaker bath maintained at 37˚C and 50 
rpm.  Before sampling, particles were separated from the media by centrifuging and the 
supernatant was collected.  All but 150 l of release media was removed per sample and 
an equal amount of release media was added prior to resuspension of the particles.  
Samples were performed in triplicate. Blank particles loaded without protein were also 
performed in triplicate.   The purposed of the blank particles was to account for any 
fluorescence caused by degraded particles. The supernatant collected was assayed for 
protein activity (EnzChek® assay).  The EnzChek® assay measures lysozyme activity on 
Micrococcus lysodeikticus cell walls, which are labeled with fluorescein such that the 
fluorescence is quenched.  Lysozyme action relieves this quenching resulting in an 
increase in fluorescence that is proportional to lysozyme activity.   
5.2.2.8 Effect of Plasma Treatment on Lysozyme Activity and pH 
 To determine the effect of plasma treated DI water and PBS on protein activity, 
2ml of water or PBS was plasma treated for the desired time intervals.  14 l of a 
lysozyme in water solution (150 g/ml) was added to 1666 l of plasma treated DI water 
or PBS.  The EnzChek™ assay was then used to determine lysozyme activity and the 
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percent of activity remaining was determined by comparing the activity of treated and 
non-treated samples.  Studies were performed in triplicate. 
 pH studies were performed in triplicate by subjecting 2 ml DI water or PBS to 
plasma treatment at various time intervals and recording the pH using a pH meter 
(Accumet Basic, Denver Instruments).  
5.2.2.9 Inactivation of Bacteria Utilizing Indirect Plasma Treatment 
 Particles prepared for the inactivation studies underwent the same preparation 
conditions as mentioned earlier.  The primary aqueous phase contained either BSA (100 
mg/ml) in PBS or just PBS.  All aqueous based solutions used to either make or wash the 
particles were sterile filtered using a 0.22 m filter.  After stirring overnight, the particles 
were collected by centrifuging.  The ‘no wash’ samples were centrifuged once, the ‘one 
wash’ samples were centrifuged, resuspended in water and centrifuged again and the ‘two 
wash’ samples were subjected to an additional resuspension and centrifugation step.  The 
purpose of the washes was to remove any PVA or free BSA.  The particle pellet 
remaining was then used for inactivation studies.  For the plasma treatment, 2 ml of 
sterile filtered DI water or PBS was subjected to plasma discharge for 0, 30, 60 or 120 
seconds.  The particles were then resuspended in the plasma treated water or PBS along 
with 100 l of E.coli at a concentration of 10
3 
CFU/ml.  Samples were then vortexed and 
remained in the treated water or PBS for at least 30 minutes prior to sampling.  For 
sampling, 100 l of the resuspension was removed and plated to measure E.coli colony 
forming units (CFUs).  Inactivation was measured as % of CFUs remaining (eq. 5.4) by 
comparing CFUs of treated samples (particles plus bacteria resuspended in 2 ml of water 
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or PBS) to the CFUs of the control (bacteria plus 2 ml of PBS).  Examples of treated and 
control samples are shown in Fig. 5.2.  Studies were performed in triplicate 
Controlin  CFUs #
Treatedin  CFUs #
 x 100 Remaining  %
 
(5eq.4) 
5.3 Results & Discussion 
5.3.1 Effect of Plasma Treatment on Particle Morphology and Protein Activity 
Due to the sensitivity of both nanoparticles and protein to current sterilization 
techniques a novel method had to be developed that maintained protein activity and 
particle integrity.  In order for non-thermal plasma decontamination to be considered as a 
potential option, the effects on protein activity, protein release and particle morphology 
had to be assessed.  When lysozyme is diluted with plasma treated water, there is a 
substantial loss of protein activity with only 26.6 ± 5.0% and 2.8 ± 1.4% activity 
remaining after treatment times of 60s and 90s, respectively (Fig. 5.3).  In order to 
maintain protein activity, lysozyme was diluted with plasma treated PBS.  The results 
indicated that plasma treated PBS is less detrimental to lysozyme activity.  68.4 ± 10.6% 
activity remained when lysozyme was diluted with PBS that was plasma treated for two 
minutes.  Because lysozyme is most active over a pH range of 6 – 9 one of the main 
differences in the damaging effects of plasma treated water versus plasma treated PBS is 
the drop in pH.  The differences in pH of plasma treated water versus plasma treated PBS 
are illustrated in Figure 5.4.  It is seen that the drop of pH out of the lysozyme working 
pH range in plasma treated water is almost immediate, dropping to a pH of 3.26 ± 0.12 
after only 15 seconds of treatment time.  However, after two minutes of plasma 
treatment, PBS only drops to a pH of 5.94 ± 0.06, just below the ideal activity range of 
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lysozyme.  It is not until after three minutes of treatment for PBS where there is a large 
drop in pH (3.46 ± 0.12) which seems to correlate with a large drop in lysozyme activity 
(7.6 ± 0.5% activity remaining).  While the exact mechanism by which plasma treatment 
decreases protein activity is not known, the drop in pH seems to play a prominent role.   
Despite losses in activity when lysozyme was resuspended directly in plasma 
treated water, there remains the potential that protein entrapped within particles can be 
shielded from the damaging effects of plasma treatment.  The average diameter of 
particles used for these studies was 535.1 ± 124.2 nm and an SEM image of untreated 
particles is shown in Fig. 5.5.  Loading and release studies were performed on plasma 
treated particles to determine the effects on loading and active protein release.  Plasma 
treatment does result in a loss of the amount of protein loaded (Table 5.1) and in the 
amount of active protein released (Fig. 5.6).  The drop in loading may result from the 
effects on surface proteins.  Plasma treatment may either cause the surface associated 
proteins to disassociate from the particles and be washed away in the wash steps 
following plasma treatment or plasma treatment may result in insoluble protein 
aggregates.  The effects on surface associated protein may also explain the activity loss 
primarily seen in the burst released protein at the start of the release study. Despite this, 
all three samples are able to deliver sustained amounts of active protein.  The initial burst 
release protein is primarily the result of the surface bound proteins immediately diffusing 
into the release media [57].  Therefore, it is possible that the plasma treatment is most 
damaging to the surface bound protein, but the entrapped protein is shielded from the 
damaging effects, resulting in a sustained release profile of active protein.  Also, because 
plasma treated water is more harmful to lysozyme activity then plasma treated PBS, one 
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method to limit the loss of active protein initially released from particles is to resuspend 
particles in plasma treated PBS instead of plasma treated water.  However, for 
resuspension of protein loaded particles into plasma treated PBS as opposed to plasma 
treated water, the plasma treated PBS must be shown capable of completely sterilizing 
the particles both with and without protein.   
Although plasma treated water showed significant detrimental effect on protein 
activity, SEM imaging showed no morphologic effects of particles resuspended in water 
treated for 30s and 60s (Fig. 5.7).   
5.3.2 Inactivation of Bacteria Utilizing Indirect Plasma Treatment 
 The difficulty with sterilizing protein loaded nanoparticles is providing adequate 
plasma treatment to allow for complete bacteria inactivation, but not providing excessive 
treatment that results in particle damage and protein activity loss.  The purpose of the 
inactivation studies was to assess the sterilization effectiveness of treatment times that did 
not result in complete protein activity loss.  Thus, the treatment times chosen were 30s 
and 60s for resuspenion in plasma treated water and 60s and 2 minutes for resuspension 
in plasma treated PBS.  Also, because BSA has been used as an additive to help limit 
protein damage, particles loaded with and without BSA were treated [74, 109, 166].  The 
potential is that particles, PVA and BSA could interfere with bacteria inactivation and 
reduce the effectiveness.  Particles made with and without BSA were resuspended in 
plasma treated water and a known concentration of bacteria was added.  The controls 
consisted of non-plasma treated PBS with the same concentration of bacteria added. The 
control sample did not contain particles because the purpose of the control was only to 
assess the amount of bacteria that is present when the sample is not plasma treated.  The 
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particles were included in the treated samples because the particles interfere with the 
ability of plasma treated water or PBS to decontaminate.  Therefore, because the control 
was not plasma treated, there was no need to include particles since there was no 
treatment for the particles to interfere with. The bacterial load used for treatment (10
3
 
CFU/ml) was well below the bacterial amounts present in particles that did not undergo 
plasma treatment (data not shown).   
 The effectiveness of indirect plasma inactivation is listed in terms of % CFUs 
remaining in Tables 5.2 & 5.3.  Zero percent CFUs remaining is considered complete 
sterilization.  Results of plasma treated water are shown in Table 5.2.  Without one wash 
step none of the particles were completely sterilized.  This indicates that residual PVA 
interferes with bacteria inactivation.  With the wash step, particles without BSA were 
completely sterilized at 30s and 60s treatment times, however, the full 60 seconds of 
treatment was required for particles with BSA.  This indicates that residual BSA 
remaining in solution and on the particle surface potentially interferes with sterilization.  
Although a low bacterial load was used (10
3
 CFU/ml) complete sterilization is considered 
because plating the treated particles onto bacteria growth agar resulted in no bacterial 
growth. 
As indicated in Fig. 5.3, plasma treated PBS is not as damaging to protein activity 
as plasma treated water.  However, because PBS buffers against the negative effects of 
plasma treatment on protein activity, it is critical to test if PBS also buffers against the 
antibacterial effects of plasma treatment.  Results of plasma treated PBS on particle 
decontamination are shown in Table 5.3.  Particles without BSA that undergo one wash 
are completely sterilized after 60 seconds of PBS treatment; however, particles with BSA 
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are not sterilized with 84.5 ± 4.7% CFUs remaining.  This indicates that the presence of 
BSA greatly interferes with the sterilizing effectiveness of plasma treated PBS.  An 
additional wash step (Two Washes) was performed to help remove more of the surface 
associated BSA, but this provided little benefit to inactivation effectiveness, potentially 
because most of the unbound protein has already been removed in the initial wash steps.  
Table 5.4 indicates the weight % of BSA in particles at each wash step.  In order to get 
complete particle sterilization, the plasma treatment time of PBS had to be increased to 
two minutes.  This is an indication that the indirect plasma treatment of PBS is not as 
effective as the indirect plasma treatment of water.  However, even with the additional 
treatment time required for complete sterilization (i.e. 2 minutes), plasma treatment of 
PBS is not as detrimental to protein activity.  Under the conditions tested, and taking into 
consideration the effect of plasma treatment on protein activity and bacteria inactivation, 
the preferred treatment method to allow for complete inactivation while maintaining 
protein activity is resuspending washed particles in 2 ml of PBS that has been plasma 
treated for 2 minutes. 
5.4 Conclusions 
 Sterilization of protein loaded PLGA nanoparticles is difficult because of the need 
to maintain particle integrity and protein activity while inactivating bacteria.  This work 
demonstrated that indirect plasma treatment of water and PBS was effective at 
decontaminating protein loaded particles when inoculated with 10
3
 CFU/ml of E. Coli.  
Plasma treated water showed no morphological effect on particles, but did result in a 
significant loss in lysozyme activity.  When exposed to plasma treated water, particles 
loaded with lysozyme demonstrated a diminished burst release of active protein, but were 
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still able to deliver active protein over several weeks similar to the particles that were not 
treated.  Exposure of lysozyme to plasma treated PBS resulted in improved retention of 
activity, potentially because of the pH buffering of PBS.  Plasma treatment of PBS did 
require additional treatment time to inactivate a bacterial load of 10
3 
CFU/ml, but the 
additional time still allowed for adequate retention of protein activity.  Ultimately, 
resuspension of particles in plasma treated PBS seems an effective way to both 
decontaminate particles and maintain protein activity. 
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Figure 5.1: DBD Experimental Setup. 
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Figure 5.2:  Bacteria inactivation set-up. 
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Figure 5.3: Effect of plasma treatment on lysozyme activity.  Error bars indicate standard 
deviation, n=3. 
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Figure 5.4: Effect of plasma treatment on pH.  Error bars indicate standard deviation, n=3. 
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Figure 5.5:  SEM image of PLGA particles without plasma treatment, 3kx magnification, scale 
bar 3 m. 
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Figure 5.6: Particle release data.  Error bars indicate standard deviation, n=3. 
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Figure 5.7:  SEM images of particles exposed to plasma treated water. (A, B) 30 second treatment 
time; (C, D) 60 second treatment time; (A, C) 1kx magnification, scale bar 10 m; (B, D) 20kx 
magnification, scale bar 500nm.  
  
30 second treatment time 60 second treatment time 
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Table 5.1: Loading Results 
Treatment Time 
(s) 
Encapsulation Efficiency 
(%)* 
Lysozyme Weight Percentage 
(%)* 
0 59.6 ± 3.4 1.19 ± 0.07 
30 53.5 ± 1.2 1.07 ± 0.02 
60 44.4 ± 2.2 0.89 ± 0.04 
* Values are listed as mean ± standard deviation (n=3). 
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Table 5.2: Bacteria Inactivation With Plasma Treatment of Water 
Substance 
Sterilized 
Water 
Treatment 
Time (s) 
% CFUs Remaining* 
No Wash* One Wash* 
Water 30 0.0 ± 0.0 ------ 
Particles – No 
BSA 
30 21.7 ± 21.0 0.0 ± 0.0 
60 1.8 ± 3.1 0.0 ± 0.0 
Particles – With 
BSA 
30 47.8 ± 13.6 10.9 ± 7.2 
60 25.0 ± 18.8 0.0 ± 0.0 
* Initial bacterial load of 10
3 
CFU/ml  
* Values are listed as mean ± standard deviation (n=3). 
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Table 5.3: Bacteria Inactivation With Plasma Treatment of PBS 
Substance 
Sterilized 
PBS 
Treatment 
Time (s) 
% CFUs Remaining* 
One Wash* Two Washes* 
Particles – No 
BSA 
60 0.0 ± 0.0 ------ 
Particles – With 
BSA 
60 84.5 ± 4.7 84.6 ± 3.9 
120 ------ 0.0 ± 0.0 
* Initial bacterial load of 10
3 
CFU/ml  
* Values are listed as mean ± standard deviation (n=3). 
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Table 5.4:  Weight % of BSA in Particles 
Number of Washes 
BSA Weight Percentage 
(%)* 
0 15.8 ± 0.7 
1 15.4 ± 0.7 
2 15.1 ± 0.6 
* Values are listed as mean ± standard deviation (n=3). 
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6. Chapter 6:  Analysis of Particle Surface Characteristics and Cytotoxicity 
Evaluation 
6.1 Introduction 
Due to the heightened immune response caused when PLGA particles were 
injected into spinal tissue, the remaining work of this thesis is done to address potential 
causes of this response.  Chapter 5 addressed concerns relating to particle contamination 
and reviewed a novel plasma treatment method that could sterilize particles post-
preparation while maintaining protein activity.  Chapter 6 seeks to address other potential 
causes of particle incompatibility.  These concerns are related to potential incompatibility 
of the surfactant used, PVA, opsonin adsorption on the particle surface and cytotoxicity 
of the particles themselves. 
Because the surfactant, PVA, that remains associated with the particle surface can 
interfere with surface characterization and because PVA has been linked with safety 
concerns [132-134], a lower amount of a different surfactant, sodium cholate (Fig. 6.1), is 
utilized for a good portion of this work because it has been shown to leave no detectable 
trace amounts on the particles [135, 136].  Plus, by using acetone as the solvent for the 
W/O/W preparation procedure, particles are formed by the polymer precipitating out of 
the organic phase and not by the formation of organic droplets.  Therefore, the additional 
solvent is not required to stabilize the emulsion droplets, only to help reduce aggregation 
after the ‘solid’ particles are formed. 
Indirect plasma treatment of particles was shown to be an adequate tool for 
decontaminating particles while maintaining particle and protein integrity.  However, 
because of the nature of the plasma treatment and the reactive oxygen species that the 
particles are exposed to, it is unclear what type of chemical modification the particles 
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undergo.  Therefore, it is necessary to assess any modifications to the particle surface by 
analysis techniques such as SEM, zeta potential and FTIR.  It is also important to 
determine the impact that any changes resulting from the plasma treatment have on 
protein adsorption to the particles’ surface. 
Opsonin adsorption to the particle surface is a concern because opsonin 
adsorption on foreign substances initiates an immune response.  One of the first 
responders to the response is macrophages.  Therefore, reducing opsonin adsorption and 
hence reducing the initial immune response is desired.  PLGA particles have been shown 
to induce protein adsorption and one of the ways to reduce protein adsorption to the 
PLGA particle surface is by the addition of PEG [135].  Multiple methods of adding PEG 
to the particle surface are utilized and their effectiveness is evaluated.   
Although PLGA is a widely accepted biocompatible polymer, concerns still remain 
with PLGA in particle form.  Cytotoxicity concerns are directly related to the immune 
response because cells that undergo cell death through necrosis release inflammatory 
signaling cues [167].  While there is substantial work reviewing the toxicity of particles < 
100 nm [140, 168-176], there is little research evaluating the cytotoxic impact of particles 
in the 100 nm to 1 m size range.   Toxicity concerns over particles that are < 100 nm are 
related to their small size and their ability to easily penetrate the cell membrane.  
Although particles ranging from 100 nm to 1 m must be actively internalized by cells, 
there is still the potential of cell damage and cell death.  It is also important to analyze 
other potential cytotoxic effects such as plasma treatment, PEGylation and PLGA 
degradation.   
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6.2 Experimental Section 
6.2.1 Materials 
Poly(lactide-co-glycolide) (PLGA, average molecular weight (MW) 18 kDa, 
copolymer ratio 50:50) was purchased from Lakeshore Biomaterials.  Sodium cholate; N-
(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC, MW 191.71 Da); 
N-Hydroxysulfosuccinimide (Sulfo-NHS, MW 217.13 Da); Sodium phosphate; Sodium 
chloride; Polyoxyethylene bis(amine) (Diamine PEG, average MW 6,000 Da); 3,6-
Dimethyl-1,4-dioxane-2,5-dione (Lactide, MW 144.13 Da); 1,4-Dioxane-2,5-dione 
(Glycolide, MW 116.07 Da); Tin(II) 2-ethylhexanoate (SnOct, MW 405.12Da); TRIS 
hydrochloride (MW 157.6 Da); 2-(N-Morpholino)ethane sulfonic acid (MES, MW 
195.24 Da); Immunoglobulin G (IgG) from human serum; and Dulbecco’s Phosphate 
Buffered Saline (PBS, pH 7.4, KCl – 0.2 g/L, KH2PO4 – 0.2 g/L, NaCl – 8.0 g/L and 
Na2HPO4 – 1.15 g/L) were purchased from Sigma-Aldrich.  Poly(vinyl alcohol) (PVA, 
average MW 25 kDa, 88% hydrolyzed), Methoxy-poly(ethylene glycol) (mPEG, average 
MW 5,000 Da), and Polystyrene beads (0.10 Micron) were purchased from Polysciences, 
Inc.  Protein concentration assay (Pierce Micro BCA™ assay) was purchased from 
Thermo Scientific.  Cell viability assay (CellTiter-Glo® Luminescent cell viability assay) 
was purchased from Promega.  All organic solvents were of HPLC grade and purchased 
from Sigma-Aldrich.  L-929 mouse fibroblast cells were donated from Dr. Michele 
Marcolongo’s Biomaterials Lab at Drexel University. 
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6.2.2 Methods 
6.2.2.1 Particle Preparation 
The first water-oil phase contained 250 l of PBS plus 2.5 ml of an organic 
solution consisting of PLGA (25 mg/ml) or mPEG-PLGA (25 mg/ml) in DCM or 
acetone.  The first water-oil phase was homogenized (Polytron® System PT3100 
homogenizer with PT-DA 3007/2EC dispersing aggregate, Kinematic, Inc, Bohemia, 
NY) for 1 minute at a speed of 25,000 or 15,000 rpm.  Only the particles made with 
DCM as the solvent were homogenized at 25,000 rpm.  The first emulsion was then 
removed and slowly pipetted into 12.5 ml of 2 % PVA or 0.1 % sodium cholate kept at 
4˚C while being homogenized at the same speed as the first emulsion.  The second 
emulsion was homogenized for two minutes.  To allow for solvent removal, the second 
emulsion was then added to 25 ml of 2 % PVA or 0.1 % sodium cholate and allowed to 
stir overnight at 350 rpm.  For all particles prepared, the same surfactant solution (2 % 
PVA or 0.1 % sodium cholate) was used throughout the procedure.  Particles were then 
collected by centrifuging at 15,000 G for approximately 30 minutes.  The particles 
obtained were washed twice in deionized (DI) water and centrifuged each time to collect.  
After the final centrifuge, the particles were refrigerated, freeze-dried or sampled for 
subsequent testing or PEGylation.  Particles used to test the effect of washing on 
removing residual PVA underwent multiple wash steps and were sampled for zeta 
potential measurement at each step.  These particles were prepared according the 
procedure mentioned above with the exception that DCM and acetone were used as the 
solvents and when DCM was used, the particles were homogenized at 25,000 rpm. 
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Particles prepared for cytotoxicity testing underwent the same procedure 
mentioned above, with the following exceptions.  All solid surfaces that came into either 
direct or indirect contact with the particles during synthesis were rinsed with ethanol to 
decontaminate.  All aqueous based solutions (PBS, water, PVA, sodium cholate) used to 
make and wash the particles were sterile filtered through a 0.22 m filter.  Particles were 
stirred overnight in a sterile laminar flow hood to allow for solvent evaporation and 
following overnight stirring were collected in sterile centrifuge tubes.  During the 
washing and centrifugation steps, centrifuge tubes were only open in the sterile hood and 
sterile conditions were maintained.  Particles were freeze-dried in a Steriflip® centrifuge 
tube (Millipore, Billerica, MA) to maintain sterility.  To ensure particle sterility, freeze-
dried samples were placed under a UV light for approximately 2 hours. 
6.2.2.2 Particle Characterization 
6.2.2.2.1 Zeta Potential 
Following the final centrifugation or plasma treatment step, particles were 
resuspended in NaCl 10
-3
 M (pH = 7.64) at a concentration of approximately 0.1 mg/ml.  
Particle samples were prepared in triplicate and zeta potential was measure using a 
Zetasizer Nano ZS (Malvern instruments, Malvern, UK) 
6.2.2.2.2 SEM 
Following the final wash, surface modification or plasma treatment steps, 
particles were resuspended in 1 or 2 ml of DI water.  A small sample of suspended 
particles was removed and diluted to an approximate concentration of 1 mg/ml.  40 l of 
this diluted sample was then pipetted onto an SEM stub and flash-frozen in liquid 
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nitrogen.  The sample was then freeze-dried and sputter coated with a platinum/palladium 
mixture prior to imaging.  Imaging was conducted on a scanning electron microscopy 
(SEM) (Zeiss Supra 50VP). 
6.2.2.2.3 FTIR 
Freeze-dried particles were compacted onto the FTIR Spectrometer (Thermo 
Nicolet Nexus 870) sampling lens for analysis. 
6.2.2.2.4 NMR 
Freeze-dried particles were dissolved in deuterated chloroform (~10 mg/ml) and 
then passed through a 0.22 m syringe filter to ensure removal of any undissolved 
particulates.  Samples were analyzed on a Varian INNOVA 500 MHz superconducting 
FT-NMR spectrometer in the Department of Chemistry at Drexel University. 
6.2.2.3 Plasma Treatment 
PLGA particles were prepared utilizing the procedure mentioned above with the 
following specifics: solvent was acetone, surfactant was 0.1 % sodium cholate, and 
homogenization speed was 15,000 rpm.  Following overnight evaporation, particles were 
washed once and subjected to direct or indirect plasma treatment.  For direct treatment, 
following centrifugation, particle pellet was resuspended in 1.75 ml of PBS (to bring the 
total volume up to approximately 2 ml), placed directly into the 2 ml grounded well and 
exposed to the plasma discharge for the desired time intervals.  For indirect treatment, 2 
ml of PBS was placed into the 2 ml grounded well, plasma treated for the desired time 
intervals and the treated PBS was used to resuspend the particle pellet.  Plasma was 
generated utilizing a power supply with continuous waveform characteristics and a 2.54 
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cm diameter high-voltage electrode made of copper and covered with a dielectric barrier 
made from fused quartz (Fig. 5.1).  Two ml of PBS or particle/PBS suspension was 
placed directly below the electrode in a grounded well that contained a 2 ml reservoir.  
The electrode was kept approximately 1.5 mm above the top surface the PBS.  Plasma 
was discharged across the PBS or particle/PBS suspension and onto the grounded well at 
a power of 3.2 W and a surface power density of 0.63 W/cm
2
.  The 2 ml well sat on a 
grounded steel base.   Following treatment, the particles remained in PBS for 
approximately ½ hour prior to washing and sampling for zeta potential measurements and 
SEM imaging.  Samples were prepared in triplicate. 
6.2.2.4 mPEG-PLGA reaction 
Methoxy poly(ethylene glycol) - Poly(lactide-co-glycolide) (mPEG-PLGA) 
reaction was a modified version of a melt polymerization reaction utilized by Dziubla et. 
al [93].  The target PLGA molecular weight was approximately 40,000 Da with a 50:50 
lactide to glycolide ratio.  All powder or solid reagents utilized for this reaction were 
lyophilized overnight to remove residual water.  Approximately, 5.7 g of lactide, 4.6 g of 
glycolide and 1.3 g of mPEG were combined in a vacuum flask and placed under a 
nitrogen purge.  A 2 wt% Tin(II) 2-ethylhexanoate (SnOct) in dichloromethane (DCM) 
solution was prepared and (486 l SnOct/DCM solution) was added to the lactide, 
glycolide and mPEG blend.  The amount of SnOct added was equal to 1 wt% of mPEG.  
The mixture was stirred under the nitrogen purge for approximately 1 hour to allow for 
the DCM to evaporate and the catalyst (SnOct) to blend with the reactants.  Reactants 
were placed in an oil bath (maintained at 135°C) and stirred under a continuous nitrogen 
purge for approximately 5 hours.  Reaction was stopped by removal from the oil bath and 
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products were dissolved in DCM and precipitated in methanol.  Precipitant was collected, 
dried and redissolved in DCM.  Solution was filtered to remove any insoluble byproducts 
and precipitated in ethanol.  Precipitate was again collected and dried under vacuum. 
6.2.2.5 PEGylated PLGA Particles 
PLGA particles utilized for PEGylation were prepared using the W/O/W 
procedure under the following conditions.  Primary aqueous phases: 250 l PBS, organic 
phase: 25 mg/ml PLGA in acetone, secondary aqueous phase: 12.5 ml of 0.1 wt% sodium 
cholate and evaporation phase: 25 ml of 0.1 wt% sodium cholate.  Primary and secondary 
emulsions were 1 and 2 minutes, respectively, at a homogenization speed of 15 krpm.  
Particles were stirred overnight to evaporate solvent and then washed by centrifuging in 
the coupling buffer (50 mM MES) prior to the PEGylation procedure. 
Washed PLGA particles were collected and resuspended in 3 ml of 50 mM MES.  
Particle/MES suspension was combined with a 300 l solution containing 60 mg of EDC 
and 60 mg of sulfo-NHS.  This mixture was stirred for 30 minutes at room temperature 
and then washed twice by centrifuging and resuspending in 50 mM MES.  Washed 
particles were collected and resuspended in 3 ml of 50 mM MES.  A ligand solution 
containing 200 mg of diamine-PEG in 50 mM MES was prepared.  3 ml of the 
resuspended particles was combined with 3 ml of the ligand (diamine-PEG/MES) 
solution and allowed to stir for approximately 3.5 hours.  Particles were then centrifuged 
and resuspended in a 100 mM TRIS / 50 mM MES solution to quench the reaction.  
Particles were then washed twice in deionized water to remove unbound reactants. 
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6.2.2.6 Protein Adsorption 
Particles used for the adsorption study were made according to the particle 
preparation procedure mentioned in Section 6.2.2.1 with 0.1 % sodium cholate or 2 % 
PVA used as the surfactant.  All mPEG-PLGA particles and PLGA particles exposed to 
plasma treatment or PEGylation were made with 0.1 % sodium cholate to eliminate any 
effects of surfactant on protein adsorption.  To assess the impact of plasma treatment on 
protein adsorption, PLGA particles were exposed to direct and indirect plasma treatment 
for times of 0 s, 30 s, 1 min or 2 min. 
Glass vials used for adsorption studies were treated with Sigmacote® (Sigma 
Aldrich, St. Louis, MO) to prevent IgG adsorption on the glass wall.  Freeze-dried 
particles used for this study were resuspended in PBS (20 mg/ml) and added to an equal 
volume of a PBS solution containing IgG (1 mg/ml).  Both solutions were maintained at 
37°C.  Blank samples were prepared by resuspending particles in just PBS (10 mg/ml).  
Resuspended particles were gently stirred for 2 hours while being maintained at 37°C.  
Following the 2 hours, the suspended particles were collected and centrifuged at 15,000 
G to separate the particles from the media.  To ensure that particles did not remain in the 
sample, the supernatant was collected and passed through a 0.22 m syringe filter.  
Control samples involved subjecting the IgG solution to the same test conditions, without 
the addition of particles.  The percent adsorbed was determined by comparing the amount 
of IgG remaining in the supernatant of the particle samples to the amount of IgG in the 
control.  Studies were performed in triplicate. 
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6.2.2.7 Cytotoxicity Studies 
Cytotoxicity studies were performed based on ISO standards 10993-5 and 10993-12 
with few modifications.  Briefly, L-929 mouse fibroblasts cells were suspended in growth 
media and plated on a 96-well plate at a concentration of approximately 5000 cells/well.  
Cells were incubated overnight (37°C and 5% C02) to allow for attachment to the 96-well 
plate.  Growth media was then removed from the wells and replaced with 100 l of the 
desired sample or control.  Freeze-dried particles were resuspended in PBS at the desired 
concentration of 0.1 mg/ml and 100 l of this suspension was added to each well.  
Particle samples were prepared using the following formulations: 
• PLGA particles made with DCM and 2% PVA (example of particles used for 
animal study) 
• PLGA particles made with DCM and 2% PVA degraded for 5 and 8 days 
• PLGA particles made with acetone and 0.1% sodium cholate (SC) 
• PLGA particles made with acetone and 0.1% SC resuspended in 2 minute plasma 
treated PBS 
• mPEG-PLGA particles made with acetone and 0.1% SC  
Control samples consisted of 100 l of just PBS, positive control was 100 l of latex in 
PBS, and negative control was 100 l of HDPE in PBS.  Once the desired sample or 
control was added, the plates were incubated for two days.  After two days, 100 l of the 
CellTiter-Glo® reagent was added and the wells measured for luminescence.  Percent cell 
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survival was determined by comparing the luminescence signal from the samples to the 
signal from the PBS control.  Samples were prepared and assayed in triplicate. 
6.2.2.8 Statistical Analysis 
Results were expressed as mean ± standard deviation and were repeated in 
triplicate.  The differences in cell survival for cytotoxicity studies were analyzed by 
ANOVA.  Statistical significance was considered at p < 0.05. 
6.3 Results & Discussion 
6.3.1 Residual PVA and Zeta Potential 
Zeta potential measurements were utilized to illustrate the effectiveness of the 
wash steps on removing residual PVA from the particle surface.  Residual PVA has the 
potential to mask the surface characteristics of the PLGA particles and reduce the overall 
negative charge typical of PLGA particles.  Therefore, reducing the amount PVA on the 
PLGA particle surface should make the particle zeta potential more negative.  The effect 
of the wash steps at removing PVA from PLGA particles made with acetone and DCM as 
the solvents is illustrated in Figure 6.2.  Traditionally, two wash steps are used for the 
W/O/W procedure to successfully remove most of the surfactant that can be removed.  
This is seen with the particles made with DCM because after the second wash the change 
in zeta potential becomes less substantial, reducing from -15.13 ± 1.70 mV after the 2
nd
 
wash to -18.37 ± 0.83 mV after the 9
nd
 wash.  This is in contrast to the particles made 
with acetone as the solvent because the wash steps have no significant impact on 
reducing the particle zeta potential (Fig. 6.2).  This indicates that the PVA is not just 
associated with the particle surface, but rather, entangled as part of the PLGA mesh.  This 
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is explained because when acetone is used as the solvent to make PLGA particles the 
particles are formed by precipitating out of solution and not by the formation of 
solvent/organic droplets.  When an immiscible solvent like DCM is used then 
solvent/organic droplets are formed.  The surfactant properties of PVA will cause it to 
remain associated at the organic-aqueous interface, or more specifically, at the 
solvent/organic droplet surface.  Thus, because the PVA is associated with the outer 
particle surface, washing the particles in water can remove most of the PVA.  However, 
when a completely miscible solvent like acetone is used, the PLGA precipitates out of the 
solvent phase and in the process can entrap PVA within PLGA particle network.  Since 
solvent/organic droplets are not formed when a miscible solvent like acetone is used, the 
requirements of a surfactant like PVA to increase the droplet stability are reduced.  
Therefore, because previous work demonstrated that the solvent acetone can be used as 
the organic phase with the W/O/W procedure and provide protein loaded nanoparticles 
capable of active protein delivery, then the surfactant stability requirements are reduced.  
This allows for the use of a lower concentration and different surfactant, sodium cholate, 
which has been shown to leave no trace amounts on particles after washing [135, 136].  
The reduced amount of surfactant associated with particles is seen with zeta potential 
results by comparing PLGA particles made with acetone as the solvent that utilized both 
2 % PVA and 0.1 % sodium cholate as the surfactants.  PLGA particles made with 2 % 
PVA had zeta potential values of -4.62 ± 0.25 mV and PLGA particles made with 0.1 % 
sodium cholate had zeta potential values of -39.33 ± 6.79 mV.  The main difference in 
these values is associated with the lack of surfactant remaining on the particles made with 
0.1 % sodium cholate as the surfactant.  Therefore, to reduce any potential interference 
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caused by residual PVA on the ability to characterize the surface, all particles made for 
analyzing plasma treatment and PEGylation effects were made with acetone as the 
solvent and 0.1% sodium cholate as the surfactant.  The other advantage to developing a 
protein entrapment / particle preparation procedure that does not require the use of 
surfactants that remains associated with the particles is the elimination of PVA 
biocompatibility concerns. 
6.3.2 Plasma Treatment 
PLGA particles were exposed to direct and indirect plasma treatment at various 
time intervals.  In all cases, SEM imaging revealed no noticeable differences to the 
particles regardless of the treatment time or the treatment method (direct or indirect) 
(Figure 6.3).  FTIR analysis also indicated no variations in the chemical bonds within the 
particles, regardless of the treatment time or treatment method (Figure 6.4 & 6.5), 
although more precise measurement methods are recommended.  On the other hand, zeta 
potential measurements revealed a slight decrease in the particle zeta potential (Figure 
6.6).  This decrease appeared within only 15 seconds of treatment time and happened 
similarly for both direct and indirect treatment methods.  It seems that after a short 
treatment time for both direct and indirect treatment, the reactive species present saturate 
the particle surface.  While it is difficult to conclude the exact chemical bonds being 
made or broken, it is clear that the bond changes result in a more negative zeta potential.  
A more negative zeta potential has multiple potential benefits.  First, because PLGA 
particles are hydrophobic by nature, they have the potential to aggregate and thus lack 
stability in aqueous based solutions.  The more negative charge results in a greater 
repulsive force between the particles and thus a decrease in the ability of the particles to 
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aggregate.  This leads to an increase in particle stability.  While the ability to redisperse 
the freeze-dried plasma treated particles in aqueous media (i.e. media) is difficult to 
quantify, the plasma treated particles were much easier to resuspend.  This is important 
because the particles are without any surfactant to act as an emulsifying agent and the 
particles must be able to flow easily without agglomerating, especially if the end goal is a 
micro-injection of a suspended particle solution.  In addition, there has been work done to 
correlate a more negative surface charge with reduced protein adsorption [144].  Plasma 
treatment has been shown to make a surface more negative and increase surface 
hydrophilicity [145].  Despite the increased hydrophilicity and increased particle stability, 
there still remains concern that the more negative charge will promote the adsorption of 
an opsonin like IgG, particularly because of its positive NH2 end groups. An alternative 
possibility is that the increase in surface charge may increase the hydrophilicity of the 
particles, lowering the ability of the hydrophobic groups within the protein to adhere to 
the particle surface. 
6.3.3 mPEG-PLGA and PEGylated PLGA Particles 
PEG was conjugated to the particle surface utilizing two distinct methods.  The 
first method involved synthesizing the copolymer mPEG-PLGA through ring-opening 
polymerization and then making particles out of the mPEG-PLGA copolymer.  The 
second method involved making the PLGA particles and then coupling diamine-PEG to 
the carboxyl end groups of PLGA.  SEM images of the mPEG-PLGA particles and 
PEGylated PLGA particles are shown in Figure 6.7.  The spectra of particles made 
utilizing both techniques are shown in Figure 6.8.  The spectra were used to determine 
the copolymer compositions from the peak integrals.  The proton in the lactic backbone (-
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O-CH*(CH3)-CO-)x was assigned at 5.15 ppm, the glycolic protons (-O-CH2*-CO-)y was 
assigned at 4.78 ppm, and the ethylene oxide protons (-O-CH2*-CH2*-)z was assigned at 
3.60 ppm (Fig. 6.8).  Conjugating mPEG directly to lactide and glycolide via ring-
opening polymerization resulted in a PLGA molecular weight of approximately 93 kDa 
with a glycolide to lactide ratio of 53:47 (Fig 6.8a).  Higher molecular weights of PLGA 
were achieved because the solvents used for precipitation were chosen to encourage 
precipitation of only higher molecular weight PLGA chains.  NMR results of particles 
that were PEGylated post-preparation by conjugating diamine-PEG to the carboxyl end 
group of PLGA are shown in Figure 6.8b.  Although the NMR results verify the presence 
of PEG, the reaction efficiency is low at only 1.67 %, meaning that of all the PLGA 
carboxyl end groups available for conjugation, only 1.67% were conjugated.  This is 
primarily because of the limited accessibility to the carboxyl end group once fabricated 
within a particle-polymer mesh.  The advantage of conjugating the mPEG-PLGA prior to 
particle encapsulation is that the amount of PEG can be controlled.  Because the hydroxyl 
end group of mPEG helps to initiate the ring-opening reaction, then in theory, every 
PLGA change is conjugated to an mPEG molecule [177].  This is beneficial to directly 
control the amount of mPEG-PLGA that is incorporated within the particle because 
mPEG-PLGA and PLGA or PLA blends can be added at any ratio.  The drawback is that 
alternative compositions in the solvent phase of the W/O/W method can have an impact 
on particle size, protein loading and release characteristics.  Plus, using the W/O/W 
method it is difficult to ensure the mPEG chains extend from the particle surface.  
Because of these reasons, an alternative method was utilized that involves the addition of 
PEG chains directly to the particle surface.  While the PEG chains are incorporated only 
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on the surface, the drawback is with the reaction efficiency.  For this direct method of 
conjugating diamine-PEG to the particle surface, the amine group of diamine-PEG is 
conjugated to the carboxyl end group of PLGA.  The difficulty comes because the amine 
group needs to be able to access the carboxyl end group of PLGA that is potentially 
entrapped within the particle.  The main advantage is that the amount of PEG needed on 
the particle surface to limit protein adsorption is lower than the amount required to 
conjugate every carboxyl end group.  Therefore, an inefficient diamine-PEG to PLGA 
reaction may be acceptable.  Another advantage to conjugating the PEG directly to the 
prepared particle is that a ligand can be attached to one end of the diamine-PEG and the 
ligand will not have to be subjected to the W/O/W procedure.  Although FTIR analysis 
was unable to verify the presence of bonds created through plasma treatment, zeta 
potential measurements revealed that some changes did take place.  The hope is that 
plasma treatment of particle can act as a tool to increase the number of functional groups 
on the particle surface. 
6.3.4 Protein Adsorption 
Protein adsorption onto particles was determined indirectly my incubating an IgG 
solution with the particles, separating the particles from the IgG solution and measuring 
the amount of IgG that remained in solution.  The effects of PVA, direct and indirect 
plasma treatment, and PEGylation before and after particle preparation were evaluated 
(Fig. 6.9).  In all cases, there was no detectable amount of IgG that adsorbed on the 
particle surface.  To ensure that the lack of adsorption was not the result of experimental 
set-up, polystyrene beads (119 nm) similar in diameter to the PLGA particles were used 
as a control.  In the case of the polystyrene beads, nearly all of the IgG (97.6 ± 0.4%) was 
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adsorbed by the beads.  This indicates that the experimental set-up was valid for 
assessing protein adsorption and the lack of observed adsorption was representative of the 
inability of IgG to adsorb to the PLGA particle surface.  While it is noted that adsorption 
characteristics may still be different under in vivo conditions, the level of concern is 
greatly reduced over opsonin protein adsorption being the cause of the macrophage 
response seen in preliminary studies. 
6.3.5 Cytotoxicity 
Cytotoxicity studies were performed by resuspending particles in PBS and then 
incubating this suspension with mouse fibroblast cells for two days.  The reason for using 
PBS as opposed to growth media to resuspend the particles was to get a true 
representation of how the particles potentially caused cell death and not just how the 
particles may have inhibited cell growth.  Particle formulation parameters were chosen to 
represent the following conditions:  particles used for the preliminary animal studies (2 % 
PVA, PLGA in DCM); particles made with minimum surfactant (0.1 % sodium cholate, 
PLGA in acetone); particles that underwent indirect plasma treatment (0.1 % sodium 
cholate, PLGA in acetone, 2 min indirect plasma treatment); particles made out of 
mPEG-PLGA (0.1 % sodium cholate, mPEG-PLGA in acetone).  The concentration of 
particles used for the preliminary in vivo studies was 0.4 g/ml which was chosen based 
on spinal tissue injections utilized by Wang et. al. [2].  However, the particle 
concentration of 0.1 mg/ml was used to determine if particles had an impact on cell 
survival.  It is important to keep in mind that the concentration of particles used for 
cytotoxicity testing is independent of the concentration used for animal testing. Once 
particles are injected into spinal tissue; the particle concentration becomes irrelevant 
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since the media is immediately diluted.  Ultimately, the concentrations chosen for 
cytotoxicity testing will exceed the concentrations under in vivo conditions.  Cytotoxicity 
data is represented in Figure 6.10.  Particles made with DCM and 2 % PVA showed a 
decrease in cell survival, but due to the large standard deviation, the decrease was 
statistically insignificant (p = 0.06).  Ultimately, there is a minimal level of concern over 
the cytotoxic nature of particles made with DCM as the solvent and 2 % PVA as the 
surfactant.  While it is difficult to definitively assess whether the decrease in cell survival 
was the result of residual solvent, surface characteristics, particle size or some other 
unknown characteristics, it is doubtful that residual solvent was the cause.  This is 
because of the extensive methods that were taken for solvent removal.  These methods 
involved an overnight evaporation step, several wash steps and high vacuum drying 
conditions.  Surface characteristics such as, surface charge, should have negligible 
impact.  For example, particles made with acetone and 0.1 % sodium cholate had a zeta 
potential of -39.3 ± 6.8 mV and particles made with DCM and 2 % PVA had a zeta 
potential of -18.37 ± 0.83 mV.  While the zeta potential value may influence the adhesion 
and interaction properties of the particles with the cells, the surface charge should not 
have a direct impact on toxicity.  There does remain a concern over safety issues relating 
to residual PVA on the particle surface, however, these safety concerns are not directly 
linked to cell death.  Rather, toxicity and cell death would most likely come from the 
likelihood of the cells to internalize the particles, either through phagocytosis or 
endocytosis, and/or the particles ability to disrupt the cell membrane.  As illustrated in 
Chapter 3, one of the main differences on particle morphology seen with the use of the 
different solvents is on particle size.  For example, particles made in DCM have an 
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average diameter of 535 nm while particles made in acetone have an average diameter of 
116 nm. Therefore, the larger size particles may be more damaging to cells and 
potentially impose a greater risk once internalized.  Plus, because the particles are added 
on top of the cells in the form of a suspension, the larger particles are more likely to settle 
on the bottom of the suspension and interact directly with the cells.  While the exact 
reason remains unclear, it is apparent that PLGA particles made with acetone as the 
solvent and 0.1 % sodium cholate as the surfactant have no negative impact on cell 
survival.  Thus, a particle preparation method has been developed that illustrates no 
cytotoxic characteristics.   
In order to analyze any cytotoxic impact of plasma treatment, the cytotoxicity of 
PLGA plasma treated particles was evaluated (Fig. 6.10).  The plasma treatment was 
consistent to the decontamination treatment used in Chapter 5 and consisted of treating 
PBS for 2 minutes and then resuspending the PLGA particles in the treated PBS.  As 
expected, plasma treatment showed no cytotoxic effects.  Direct plasma treatment has 
proven non-damaging to living tissue [178] so no toxicity was expected by the indirect 
treatment of particles.  Plasma treatment and the introduction of ions on the material 
surface have actually been shown to facilitate cell proliferation [145, 179].  This may 
explain why the % cell survival of plasma treated particles is slightly above 100 %.  In 
contrast, fabricating particles out of mPEG-PLGA resulted in a significant loss in cell 
survival with a survival rate of 74.6 ± 3.6% when compared to the control (Fig 6.10).  
The main potential contribution to these results is that the addition of PEG to the particle 
surface better enables the particles to penetrate the cell membrane.  Particle 
internalization may directly relate to cell damage.   
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The effect of PLGA degradation on cytotoxicity is shown in Figure 6.11.  Particles 
used for this study were representative of particles used for the preliminary in vivo studies 
(2 % PVA and 25 mg/ml PLGA in DCM).  Although the time frame studied is well 
below the degradation time of PLGA, it is consistent with the time frame utilized in the 
preliminary in vivo studies.  Therefore, if PLGA degradation had an impact on the 
immune response observed, it would have needed to happen within the eight day duration 
of the study.  Concerns over toxicity caused by PLGA degradation are mainly linked to 
pH changes caused by the acidic degradation products of lactic and glycolic acid.  Figure 
6.11 shows that PLGA particles incubated for 5 and 8 days prior to the start of the study 
had no effect on cytotoxicity when compared to PLGA particles that underwent no 
degradation.  Also, concerns over pH changes caused by the degradation products of 
PLGA are minimized with an in vivo application because any pH changes will be 
buffered by spinal fluid. 
6.4 Conclusions 
Because of the presence of residual PVA when 2 % PVA was used as the 
surfactant, altering the preparation conditions by the use of 0.1 % sodium cholate and 
acetone allowed for particle formation without residual surfactant on the particle surface.  
Other surface modification methods included ways to increase surface hydrophilicity and 
these methods involved both PEGylation and plasma treatment.  Plasma treatment 
resulted in a more negative zeta potential, but no measurable change in chemical bonds.  
PEGylation done by PEGylating PLGA before and after particle preparation resulted in 
PLGA particles conjugated with PEG.  Original particle preparation and modification 
methods resulted in no measurable amount of protein (IgG) adsorbed to the particle 
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surface.  Particles prepared under the same formulation parameters as those used for the 
preliminary in vivo studies (2 % PVA and 25 mg/ml PLGA in DCM) showed some 
cytotoxicity, but the results were statistically insignificant (p = 0.06).  Minimizing the 
amount of surfactant required by using acetone and 0.1 % sodium cholate resulted in 
particles that showed no signs of cytotoxicity.  Plasma treatment showed no cytotoxic 
effects, while mPEG-PLGA showed minimum cytotoxicity.  Eight day PLGA particle 
degradation showed no impact on cytotoxicity.   
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Figure 6.1: Sodium Cholate [Sigma Aldrich]  
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Figure 6.2: Influence of washing PLGA particles and impact on zeta potential.  Error bars 
indicate standard deviation, n=3. 
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Figure 6.3: SEM Images of direct and indirect plasma treated particles.  Magnification 25 kx.  
Scale bar 500 nm.  
No Treatment 
Direct – 1 min 
Direct – 3 min 
Indirect – 1 
min 
Indirect – 3 
min 
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Figure 6.4: FTIR of non-treated and direct plasma treated PLGA particles. 
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Figure 6.5: FTIR of non-treated and indirect plasma treated PLGA particles.  
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Figure 6.6: Zeta potential of plasma treated particles.  Error bars indicate standard deviation, n=3. 
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Figure 6.7: mPEG-PLGA and aminePEG-PLGA particles.  Magnification 10 kx.  Scale bar 1 m. 
  
mPEG-PLGA 
AminePEG-PLGA 
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Figure 6.8: NMR of PEG-PLGA particles. (A) mPEG-PLGA (B) PEGylated PLGA 
particles.   
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Figure 6.9: Protein (IgG) adsorption.  Particle type: Polystyrene, PLGA, and mPEG-PLGA.  
Surfactant: 2% PVA and 0.1% sodium cholate (S.C.).  Particle treatment: PEGylation, Indirect 
and Direct plasma treatment of 30s, 1min, and 3min time intervals.  Error bars indicate standard 
deviation, n=3. * No detectable amount of protein adsorbed.  
 
 
 
  
* 
*       *       *       *       *      *       *       *       *       * 
163 
 
 
 
 
Figure 6.10:  Cytotoxicity of PLGA particles made with DCM and 2% PVA, PLGA and mPEG-
PLGA particles made with acetone and 0.1 % sodium cholate, and PLGA particles made with 
acetone and 0.1 % sodium cholate that underwent plasma treatment.  Error bars indicate standard 
deviation, n=3.  * Indicates significant loss in % cell survival, p < 0.05.  #, p = 0.06. 
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Figure 6.11: Effect of particle degradation on cytotoxicity.  Error bars indicate standard deviation, 
n=3.  
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7. Chapter 7:  Future Recommendations 
7.1 Future Recommendations for PLGA Nanoparticles for Spinal Cord Repair 
This work has addressed multiple drawbacks that would limit the use of PLGA 
nanoparticles as a delivery system that can be injected directly into spinal tissue.  Main 
issues regarding adequate protein loading, protein stability and complete active protein 
released were resolved by adjusting the formulation parameters such as solvent 
miscibility, energy input and the use of additives.  The other main issue involved the 
amplified immune response seen in preliminary studies.  The potentials for such a 
response involved particle contamination, residual surfactant irritation, protein adsorption 
and particle cytotoxicity.  A novel plasma treatment method was developed to 
decontaminate particles post-preparation.  Formulation parameters were adjusted to 
reduce residual surfactant on the surface.  Methods such as PEGylation and plasma 
treatment were used to increase particle hydrophilicity and decrease the potential for 
protein adsorption.  However, in vitro studies indicated that an opsonin protein did not 
adsorb to the particle surface.  Cytotoxicity studies indicated statistically insignificant cell 
death when particles were prepared under representative formulation conditions used in 
preliminary animal studies (2% PVA, 25 mg/ml PLGA in DCM) in the size range of 0.53 
m.  Particles prepared with acetone as the solvent and 0.1% sodium cholate as the 
surfactant showed no cytotoxicity.  Particles prepared with acetone as the solvent also 
demonstrated sufficient protein loading, limited protein damage, the highest percentage 
of active protein release and the ability to be prepared with minimal surfactant.  
Additional cytotoxicity studies demonstrated that plasma treatment and particle 
degradation over 8 days had no damaging effects.   
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Therefore, the first future recommendation is to repeat the in vivo animal studies 
with particles that have been plasma treated post-preparation.  While larger size particles 
over 0.5 m did show some detrimental effects on cell survival, the main cause of the 
immune response is believed to be the injection of particles that were not sterile.  
Therefore, because a method was developed that can maintain particle and protein 
integrity, plasma treatment can eliminate the lack of sterility as the potential immune 
response cause. 
By eliminating the potential of injecting non-sterile particles, further in vivo 
evaluation of particles as a spinal tissue injectable system can be conducted.  Because 
formulation parameters can be manipulated to control particle size while still providing 
active protein release, these studies should include further evaluation of the effect of size 
on biodistribution.  If particles made with 2% PVA as the surfactant produce an immune 
response, then the next step is to utilize particles made with 0.1% sodium cholate and 
acetone for in vivo testing.  Finally, by using the physical encapsulation W/O/W method 
for loading proteins, particles can be loaded with therapeutic proteins such as 
neurotrophic factors (NTFs) or chondroitinase ABC.  Then the particles can be injected 
accordingly to create the necessary concentration gradients for nerve growth and 
regeneration. 
7.2 Protein Loaded PLGA Particles for Tissue Engineering 
Perhaps one of the fastest growing areas in the field of biological and biomedical 
research is in the field of tissue engineering.  One of the primary subsets within the tissue 
engineering field is the use of polymeric scaffolds and biomaterials.  Polymers have 
gained wide use in this field because of their ability to mimic biomechanical properties of 
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tissue.  However, for polymeric scaffolds and biomaterials to gain in value and use they 
must also mimic the physiochemical properties of tissue.  Because tissue involves a 
complex assortment of proteins, then for biomaterials to properly mimic tissue they must 
have a similar protein make-up and typically one that involves in-growth of the 
surrounding tissue.  Thus, the use of biodegradable particles as a delivery device for 
sustaining protein levels within scaffolds and biomaterials has a great value.  Based upon 
the results presented in this research, protein loaded particles can be prepared, sterilized 
and added directly to the tissue engineered scaffold.  Thus, the incorporation of proteins 
into the scaffold does not have to sacrifice the mechanical properties because the particles 
can be added after the scaffold is prepared.   
7.3 Plasma Treatment and Targeted Delivery 
Targeted nanoparticle delivery offers promise because of the ability to deliver the 
drug directly to the target area.  The target itself can involve any number of objects 
ranging from cancer cells to chondroitin sulfate proteoglycans (CSPGs).  Regardless of 
what the target it, targeting the nanoparticles involves the conjugation of a ligand that is 
specific to the desired biological compound.  Poly (ethylene glycol) (PEG) added to the 
particle surface is the most common linker used to both increase the particle circulation 
time and conjugate the targeting ligand.  One of the main drawbacks to conjugating PEG 
to the particle surface post-particle preparation is the inefficiency of any PEGylation 
reactions because of the absence of functional groups to conjugate the PEG.  This 
research demonstrated only a reaction efficiency of 1.67% when conjugating diamine-
PEG to the carboxyl group of PLGA particles.  The benefit of plasma treatment is the 
potential addition of functional groups while maintaining particle integrity.  Further work 
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is needed to determine and tailor these functional groups to increase the PEGylation 
reaction efficiencies. 
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